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Chapter 1 
INTRODUCTION 
The liver is a highly complex organ in which many different metabolic processes take place. 
These include the metabolism of dietary carbohydrate, protein and fats, the storage of iron, 
the formation of hormones and blood coagulation factors and the removal of toxins from the 
bloodstream. Liver transplants are required when liver function has dropped to below 20% of 
normal I. This can be a result of chronic liver failure, where liver function declines 
progressively, usually over a period of years, or acute liver failure. The main chronic diseases 
in adults are cirrhosis, alcohol-induced and non-alcoholic, and hepatitis. In children, the main 
cause is biliary atresia and other inherited anatomic and metabolic disorders. Acute liver 
failure is nonnally caused by viral hepatitis or toxic drugs. Acute liver failure is less common 
than chronic liver failure, but results in brain damage through inflammation and fluid 
accumulation in the brain, and in 75% of cases the patient dies within a few days of onset2,3. 
In the few cases where the patient does survive, the liver appears to have an amazing ability to 
regenerate. 
Thus far, patients with liver disease are handicapped by the lack of satisfactory means of 
artificial support comparable to renal dialysis. The transplanted liver must function efficiently 
from the time of transplantation, or the patient may be lost. Despite these and other 
difficulties, the therapeutic power and appeal of liver transplantation has had a considerate 
impact in the treatment of liver failure. Almost all patients with nonneoplastic chronic liver 
disease can at least be considered for liver transplantation, and even some of those with 
malignant tumors may benefit. Acute liver disease was rarely suggested as a reason to 
consider liver transplantation until the mid 1980s, but now transplantation of patients with 
fulminant hepatitis is common. Patient survival of more than 20 years after liver 
transplantation has been achieved. 
The limiting factor for greater use of liver transplantation is the availability of donor organs . 
.An estimated 80% of the patients with acute liver failure die while being on the waiting lise, 
whereas another 15% of patients with chronic liver failure are not eligible for transplantation, 
because of other concomitant disease. The shortage of donor organs and the capacity of the 
liver to regrow after damage has led to a high level of interest in the development of liver 
assisting therapies. A method to assist the failing liver may keep the patient alive, either until 
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the patient's own liver regenerates or, in the case of irreparable liver damage, a human donor 
liver becomes available and the patient can receive a transplant. 
Throughout the past 40 years many approaches to assist the failing liver have been developed 
and to date, most of them are still under investigation. The clinical outcome of the various 
approaches has been different as measured by temporary or permanent improvement of the 
patients' condition. When measured in overall survival rates, the equivalent of liver 
transplantation has never been achieved. This may be partly due to the fact that the 
mechanisms in liver failure remain unclear. Improvement of the biochemical parameters of 
the patient alone, e.g. a decrease in concentration of ammonia or bilirubin, is usually not 
related to the patients' clinical condition and vice versa4. Therefore, the methods involving 
extracorporeaJ perfusion through membranes which do not contain hepatocytes, called passive 
detoxification, do not eventually improve the patients state of diseases.ls . However, the 
treatment of patients with liver assist devices containing hepatocytes, which are thought to 
replace the multiple and complex functions of the liver more completely, presents a whole 
new era of difficulties. First of all, human hepatocytes are sparse, because of the shortage of 
donororgans. Secondly, thus far, a culture system with stable viability and differentiated 
function of primary hepatocytes has not been established. Also, the use of human cancer cell 
lines (hepatoma cell lines), which does provide a stable culture system, introduces the danger 
of infecting the patient with cancer. Thirdly, an alternative source of hepatocytes, e.g. liver 
cells from other species, may be limited due to immunological barriers. Thus, in order to be 
able to improve the clinical condition of patients with liver failure even for a short period of 
time, these methods need further investigationI6-34 . 
It is known from studies as early as the 1960s, that the liver has a privileged position in 
xenogeneic circumstances. Extracorporeal liver perfusion studies have been performed taking 
livers from dogs and pigs without major immunological drawbacks35 and liver replacement 
was successfully performed in dogs without long term immunosuppression, where a 
surprising number of dogs continued to thrive for years, some without signs ofrejection36 . An 
important advantage, when short term use of assisting liver therapies is considered, is the 
relative resistance of the liver to complement- and antibody-mediated rejection. In 
xenotransplantation, when organs are transplanted in a discordant situation, this complement 
mediated rejection, the hyperacute rejection, is a major barrier. For instance, kidneys and 
hearts may be hyperacutely rejected within hours in patients whose serum contains cytotoxic 
antibodies of the IgG class which are directed against HLA and other antigens in the donor. 
The pathogenesis of hyperacute rejection includes obstruction of the microvasculature of 
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nonhepatic grafts with clotting products and formed blood elements. However, livers are 
spared this fate in most cases37-40, and what can be expected clinically is an unusually 
vigorous cellular rejection that can be treated with aggressive conventional 
immunosuppression. The practical implication is that a negative cytotoxic crossmatch, a 
necessary condition for transplantation of other organs, is not required for successful liver 
transplantation. Moreover, it has been established that the liver can provide a protective 
screen for otheIVVise vulnerable kidneys in highly sensitized recipients who need both a liver 
and a kidney. In such patients who receive a liver first, the titer of antidonor antibodies is 
drastically reduced during the first few hours after hepatic revascularisation, making it 
possible to safely insert a kidney from the liver donor41 . However, overstatement of the case 
for the liver's privileged status could lead to erroneous conclusions about the practical 
requirements for immunosuppresive therapy following hepatic transplantation or the impact 
of xenogeneic temporary liver support. When routine biopsies are obtained in patients after 
orthotopic liver transplantation, histopathologic evidence of rejection can be found in more 
than two-thirds of patients and control of hepatic rejection may be difficult 42. 
In short, mortality figures in liver failure remain high, because of the shortage of donor organs 
for liver transplantation and the lack of satisfactory means for temporary treatments of 
patients with liver failure to bridge to either liver regeneration or liver transplantation. 
Therefore, in this dissertation we concentrated on further investigation of the various 
approaches of temporary extracorporeal liver support considering the exceptional role of the 
liver in its xenogeneic environment. 
OUTLINE OF THE DISSERTATION 
Although liver assisting therapies have been around for several decades, thus far, no 
satisfactory temporary treatment for patients with acute liver failure has been found. Chapter 
2 evaluates the different approaches towards a solution for this problem and enlightens its 
immunological implications. 
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One of the possible solutions for temporary liver support therapy is the use of the biologic 
substrate, i.e. hepatocytes, in combination with artificial material to form a bioartificialliver. 
Critical to the successful development of this technique is the ability to foster long term 
viability and function of a large cell mass in a relatively small volume, since freshly isolated 
hepatocytes take as much as one week in culture to fully re-express differentiated functions, 
the dialysis volume should not exceed 500 ml and long treatment periods are anticipated. In 
chapter 3, a hepatocyte culture system is introduced, which uses the collagen sandwich 
culture system, that provides a long term stable culture of hepatocy'tes, scaled up through the 
use of microcarriers. 
Another technique to support patients with liver failure using the biologic substrate is the 
extracorporeal pig liver perfusion, where the whole organ of the animal is connected in 
parallel to the patient with liver failure. In order to determine whether this technique may 
provide adequate support without the possible immunological disadvantages, we studied this 
method in an autogenous extracorporeal pig liver perfusion model. The results are described 
in chapter 4. 
The absence of hyperacute rejection in the above mentioned discordant xenogeneic liver 
support techniques, may partly be due to the fact that patients with liver failure have by 
definition an impaired liver function, which results in a decreased amount of circulating 
complement, the major contributor to hyperacute rejection. In chapler 5, the possibility of 
prevention of the hyperacute rejection by inducing acute liver failure in a guinea pig heart to 
rat transplantation model is described. 
The exceptional position of the liver regarding xenogeneic support of liver failure was shown 
by the absence of hyperacute rejection in a guinea-pig to rat liver transplantation model. In 
order to study the immunological pathways of a discordant xenogeneic rejection as may be 
found in a pig-to-human situation, a sensitized rat anti-hamster model was developed to 
examine the mechanism of hyperacute rejection of liver grafts, the results of which were 
compared to heart xenografting. The outcome of this study is described in chapter 6. 
Although no hyperacute rejection in ex vivo whole liver perfusion has been shown, humoral 
damage to the liver tissue can be established. Transgenic organs are being used to diminish 
humoral damage to the ex vivo perfused liver and therewith possibly improving the long term 
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use of this liver support therapy. In chapter 7 the function and the immunopathological 
features of the isolated normal and transgenic rat liver perfused with human serum are 
described. 
The use of xenogeneic biologic material in the treatment modalities of patients with liver 
failure introduces several health hazards. In an already immunocompromized patient, short-
and long-term immunological problems can be expected, and transmission of viral material to 
the patient is possible. In chapter 8 the problems encountered in the interaction between the 
xenogeneic device and the patients with liver failure are discussed and directions for future 
research are given. 
In chapter 9 the content of the above mentioned chapters is summarized. 
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ABSTRACT 
Objective and background Because of the shortage of available donor organs, mortality rates 
due to liver failure remain high. Therefore, several temporary liver -assi sting therapies have 
been developed. This paper offers a review of various approaches to temporary liver support 
as well as present immunological and metabolic developments towards a solution for this 
problem. 
Methods and Results This paper is composed of a review of the literature, which has been 
obtained through searches in Medline and additional library searches to obtain further 
references. Only papers with a well-defined aim of the study and methodology as well as a 
clear description of the outcome of the experiments were included. 
Conclusions Renewed interest has developed in old and new methods for an extracorporeal 
approach to the treatment of acute liver failure. Although temporary clinical improvement has 
been established, further research is needed to achieve a successful long-term clinical 
outcome. New developments in the field of genetic modification and tissue engineering await 
clinical application within the near future. 
INTRODUCTION 
Because of the life-threatening complications of acute liver failure (ALP), 75% of the patients 
die within a few days of onset. At present there is no satisfactory treatment for ALP except 
liver transplantation. Although liver transplantation is very successful, with 5-year survival 
rates ranging from 70 to 80 %, there is a shortage of available donor organs. It is estimated 
that in the United States only 20% of the patients with ALP receive a transplant; 80% die 
while on the waiting list 1. The clinical need for an alternative is two-fold: first, to bridge the 
gap until liver transplantation in case of irreversible damage, and second, to gain time for 
regeneration of the damaged liver. 
Various liver-assisting therapies have been introduced since the early 1960s, including 
plasmapheresis, hemodilution, and cross-circulation, but none of them led to a significant 
clinical improvement. At the same time, extracorporeal whole liver perfusion was developed, 
with promising results. This method was abandoned in the early 1970s, however, because of 
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the successful development of orthotopic liver transplantation and awareness of the possible 
immunological implications. At present, the consensus is that the multiple and complex 
functions of the liver can be replaced only by using the biological substrate (i.e. hepatocytes), 
whether in a whole liver or in combination with artificial material. This has led to increasing 
interest in the development of a bioartificialliver along with extracorporealliver perfusion. 
In addition to the worldwide shortage of available donor organs, new developments have 
made it worthwhile to pursue these solutions to the problem of ALF. The disadvantages and 
long-term effects of liver transplantation have become clear: a major and costly surgical 
procedure and lifelong immunosuppressive therapy. Furthermore, the possibility of 
genetically modifying donor animals creates an unique opportunity to overcome potential 
immunological barriers between species. In this review, we will assess the various approaches 
to a temporary solution for ALF; their shortcomings will be discussed and directions for 
future research suggested. 
EARLY LIVER SUPPORT THERAPIES 
Acute or 1i.llminant hepatic failure, usually induced by chemical or viral hepatitis, is highly 
lethal, with a death rate of more than 75% as a result of life-threatening complications such as 
portal hypertension, variceal bleeding, ascites, and hepatic encephalopathy. While the patient 
is waiting for possi ble liver transplantation, current treatment consists of intensive clinical 
support: fluid and hemodynamic support, correction of electrolyte and acid-base 
abnormalities, respiratory assistance and treatment of cerebral edema. In the past, it was 
thought that encephalopathy and cerebral edema were caused mainly by dialyzable toxins 
such as ammonia, false neurotransmitters, phenols, aromatic amino acids and other substances 
with a molecular weight below 5,000 2; early liver support systems focused on blood 
detoxification. A kidney dialysis machine was used to remove blood ammonia but did not 
result in clinical improvement 3. Because most of these toxins were thought to be protein-
bound and traditional hemodialysis used cellulose membranes impervious to large molecules, 
polyacrylonitrile membranes were introduced that allowed passage of molecules up to a 
molecular weight of 15 kDa. Table I summarizes the results of the early liver support 
therapies introduced in the 1950s and 19605. In two groups treated with hemodialysis, 4,5 
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temporary improvement in mental status and duration of survival occured in more than half of 
the patients, suggesting at least partially effective removal of neurotoxins. 
Hemofiltration has seen only limited application because of its major complication of 
thrombocytopenia, leading to bleeding in patients with an already compromised clotting 
system 6,7. Exchange transfusion showed initial improvement in neurological status in several 
trials, but no effect on the death rate was found ~_12. With the less laborious technique of 
plasma exchange or plasmapheresis, 13-15 significant improvement in neurological status and 
biochemical profiles and decreased bleeding episodes were demonstrated; control of the 
hemorrhagic diathesis was achieved through the addition of coagulation factors. With this 
method, a better overall survival rate was achieved (34% versus 14% in the non-treated 
group); however, this was a nonrandomized study and the groups were not controlled for 
cause or severity of the underlying disease 16. 
Table 1. Patients treated with earlv liver-support therapies 
Neurologic improvement 
Support System No. of patients Yes No Uoliown Survival 
Hemodialysis 4.5 65 33 17 15 17 (26%) 
Hemofiltration 6.7 15 10 5 0 8 (53%) 
Exchange transfusion ~·12 ,8 2, 16 8 9 (19%) 
Plasma exchange 13·15 32 15 17 0 7 (22%) 
Resin hemoperfusion 17,18 9 5 4 0 0(0%) 
Charcoal perfusion 2C·23 278 73 101 10, ll6 (42%) 
In hemoperfusion or plasma perfusion, the blood or plasma of a patient with ALF is perfused 
through a column containing activated charcoal or anion exchange resins. The latter caused no 
significant improvement, mainly because of early saturation of the resins and non-selective 
binding of the cations removed 17,18. After resolving the problems of platelet loss and 
hypotensive reactions by coating the columns and administering prostacyclin as a protective 
agent for the platelets 2.19, charcoal hemoperfusion yielded encouraging survival rates among 
patients with ALF 20-23. However, none of these studies included a proper control group 
defined by both the cause of the hepatic failure and the stage of the disease. Thus, the effect of 
coated charcoal perfusion cannot be estimated conclusively. This technique is still in use 
because of the possible beneficial effect in combination therapies, where it is supposed to 
protect the adjacent liver support therapy from toxic substances. 
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The detoxifying function of the above-mentioned techniques may in itself not be enough to 
improve the survival of patients with ALF. It remains to be determined whether these 
techniques, in combination with other liver-support therapies will playa role in the future. 
BIOARTIFICAL LIVER 
The limited success of detoxifying liver support therapies and improved techniques for 
culturing isolated hepatocytes that express high levels of differentiated liver function in vitro 
have lead to the development of the hybrid or bioartificialliver (BAL). These systems consist 
of biologic components (freshly isolated pig hepatocytes or human hepatoblastoma cell lines) 
in a synthetic framework. Isolated hepatocytes have been used in two ways, extracorporeal 
hepatocyte bioreactors and implantable hepatocyte systems; the latter is beyond the scope of 
this paper. In the extracorporeal bioreactors the blood or plasma of the patient with ALF 
comes in contact with the cultured hepatocytes through an ex vivo perfusion system, as in the 
hemodialysis system for patients with renal insufficiency. 
To create an artificial system containing viable hepatocytes, the procedure of culturing 
hepatocytes while maintaining their liver-specific function had to be improved. Culturing 
hepatocytes in suspension or in plastic tissue culture dishes causes the cells to loose their 
function within 24 hours and leads to cell death within days 24,25. Two solutions to this 
problem are being investigated: the use oftransfonned cells or cell-lines, and optimization of 
the culture system for primary isolated hepatocytes. Another problem is how to expand the 
cell cultures to obtain sufficient quantities of hepatocytes in a relatively small volume to 
replace completely the function of a human liver 26. Over the past 10 years, the development 
of clinically applicable BAL systems has focused on the volume of hepatocytes necessary to 
replace temporarily the liver function of the patient with ALF. 
Hepatocytes in Suspension Cultures or Encapsulated in Hydrogels 
Hepatocytes were first used in a liver support system in a clinical setting in 1987 by 
Matsamura et al. (Table 2) 27, Hepatocytes in a suspension culture were separated from the 
patient!s blood by a cellulose acetate dialysis membrane. In this single patient, some clinical 
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improvement was found. Because in vitro studies showed that hepatocytes function better 
when attached to a substrate, another attempt to establish a suspension system was made by 
Margulis et aL 28, who seeded liver cells on Biosilon microcarriers. They demonstrated 
improved survival rates in the treated group (63%) versus the group that received standard 
medical treatment (41%). However, randomization for the stage of liver disease was not 
performed in the different groups, and no follow-up cases have been reponed. Further in vitro 
studies demonstrated poorly preserved hepatocyte function after several hours of application 
28.29 
A rotating-disk type of artificial liver system, with hepatocytes entrapped within a calcium 
alginate hydrogel, showed ammonia metabolism and urea synthesis in in vitro studies and 
subsequently significant removal of ammonia in an ex vivo animal study 30. Drawbacks of 
this system are the tendency of the gel phase to dissolve during hemoperfusion, with 
consequent loss of viability of the entrapped hepatocytes. This is why it was never applied in 
a clinical setting. 
Table 2. Patients treated with artificial liver devices 
Neurologic Iml!royement 
SUJJl!ort System No. of Pts. Yes No Unknown SUr\'iYal OLT 
Suspension culture 27.~8 60 60 0 38 (63%) 0 
ELAD <15.46 
" 
18 5 1..t (61%) 3 -, 
Bioartificialliver 5:: 31 30 I 22(71%) 21 
OL T, orthotopic liver transplantation 
NlultiRlated Hepatocyte Monolayers 
The system, which best resembles an in vitro culture of hepatocytes, was designed by Uchino 
et al. in 1988 31. Hepatocytes were isolated from a canine liver and cultured on collagen-
coated borosilicated glass plates in a monolayer. Stacking 200 plates in a transparant acryJ 
resin module yielded about 80 g of hepatocytes, or one-third of a canine liver, with stable 
function of the hepatocytes for 14 days. When this device was used to treat anhepatic dogs, 
clearance of ammonia was demonstrated in the treated group (vs. the groups receiving no 
treatment or plasma perfusion) and led to a significant increase in overall survival (55 vs. 24 
hours). The same system has been used in in vitro studies of pig hepatocytes, which were 
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perfused with plasma from pat ients with hepatic failure 32, and in the testing of in vitro 
hepatocyte culture techniques such as coculture and collagen-sandwich culture 33,34 . These 
studies yielded the same encouraging results in vitro, but thus far no report of a clinical 
applicat ion has been published. 
Hollow Fiber Systems 
Most devices used to create a SAL consists of a bundle of small-diameter tubes, made of 
compatible cellulose acetate, enclosed in a rigid polycarbonate module (Figure 1). This 
hollow fiber system has two compartments (intraluminal within the fibers and extraluminal 
outside the fibers) within the rigid housing; they communicate through the pores in the fiber 
walls. Due to the fact that most of the waste molecules and bilirubin are bound to albumin 
(molecular weight 65-70 kDa), the pore size chosen is usually a nominal molecular weight 
cutoff of 100 kDa; this excludes most complement factors and immunoglobins 35. 
figure I 
Figure 1. 
1 
4 
I. plasma reservoir 
2. pump 
3. charcoal reservoir 
4. oxygenator 
5. plasmapheresis 
hepatocyte 
bioreactor 
hollow fibers 
Liver support device. After plasmapheresis, plasma circulates through a hollow 
fiber system in which isolated pig hepatocytes are cultured in the extracapillary 
space. 
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Intraluminal gel-entrapment qf porcine hepatocytes 
Prolonged viability and functioning of the hepatocytes are difficult to maintain at a high 
seeding density in an artificial liver The viability and liver-specific functioning of 
hepatocytes are maintained by meeting several conditions, such as culturing on specific 
eX"tracellular matrices 36.37, using a hormone-enriched culture medium 38,39, and ensuring 
three-dimensional orientation of the cultured hepatocytes 37. Gel-entrapment of hepatocytes 
allows most of the above. In these bioreactors, the primary isolated hepatocytes are inoculated 
into a collagen suspension within the intraluminal fiber space. The solution rapidly gels, 
resulting in hepatocytes entrapped in a three-dimensional matrix in the hollow fibers. The 
hepatocyte/collagen gel subsequently contracts to less than 50% of the original cross-section, 
resulting in three compartments: the contracted gel containing the hepatocytes, the rest of the 
intraluminal hollow fiber space, and the extraluminal space within the rigid housing. 
Hepatocyte culture medium is perfused through the intraluminal space to keep the hepatocytes 
viable and functional when another medium (in the future the patient's blood) is perfused 
through the extraluminal space. Proper functioning of this bioreactor has been demonstrated 
for 5 consecutive days in vitro, as measured by albumin synthesis, ureagenesis and oxygen 
consumption 40. In an animal model of hepatic failure in small dogs «30kg), improved 
hemodynamic stability, delayed or absent hepatic encephalopathy, and improved survival 
were shown 41. Unfortunately, this concept yields only 0.5 to 1.0 g cells per bioreactor 42, 
which is not enough to treat humans. Although further characterization studies are being 
performed 43, the distance required for nutrients and exchangeable medium of the intraluminal 
gel-entrapped hepatocytes is not known, whereas the whole process of exchanging nutrients 
and toxic substances is dependent on passive diffusion through this gel. 
Extracorporealliver-assist device, ELAD 
The C3A cell line is a highly differentiated, stable, and viral-free human cell line that 
performs a range of metabolic functions comparable to those of the normal liver. It has been 
shown to maintain viability and function for 4 to 8 months when seeded in a hollow fiber 
cartridge at high seeding density. In this concept, approximately 10 g ofC3A cells is injected 
into the extraluminal space; the cells grow to confluence in a period of 3 to 4 weeks and do 
not outgrow their culture space. Ivlaturity is determined by glucose use and albumin 
production. It is thought that approximately 200 g of C3A cells (2x10" hepatocytes) are 
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seeded in the bioreactor at confluence 44. Animal studies of dogs with acetaminophen-induced 
hepatic failure showed a significant biochemical improvement and improved survival. 
However, although the fibers have a nominal molecular weight cut-off of 70 kDa, human 
proteins such as human transferrin (molecular weight 90 kDa) and aI-antitrypsin were 
detected in dog serum, suggesting the transfer of human cell line material to the (canine) 
patient 44. Initial experience was encouraging: 11 patients were treated with the extracorproeal 
device and no short-term safety problems were observed; 10 patients showed biochemical 
improvement and 6 patients survived (see Table 2) 45. In a second study, a pilot controlled 
trial, Ellis et al 46 reported good survival for the treated group (78%), but surprisingly also for 
the group receiving conventional treatment (75%). The authors attribute the outcome of this 
trial to their choice of a group of patients with ALF at an earlier stage of the clinical course, 
when accurate predictors of prognosis are lacking. Further clinical studies will have to be 
performed to be able to justify the use of this system for patients with liver failure. More 
importantly, the long-term effects of leakage of human cell line material into the circulation of 
future patients, as previously shown 4i, need to be assessed before the safety of this system 
can be established conclusively. 
B;oart!fiCialliver, BAL 
Because hepatocytes are known to be anchorage-dependent for prolonged viability and 
functioning, and to increase the effective surface area for hepatocytes in the hollow fiber 
cartridge, Demetriou et al 48 used collagen-coated microcarriers for their BAL. After isolation 
of primary pig hepatocytes, the cells are incubated overnight with collagen-coated dextran 
microcarriers for attachment, and the microcarrier-attached hepatocytes are inoculated into the 
extraluminal compartment of the hollow fiber system. In vitro and in vivo studies showed 
hepatocyte viability and functioning on microcarriers by conjugation of bilirubin, uptake of 
99111Tc -DESIDA, and synthesis of liver-specific proteins (e.g. albumin) after implantation in 
albumin-deficient rats for 6 days. Moreover, similar functioning was measured after 2 weeks 
of storage of the microcarrier-attached hepatocytes at -80°C, suggesting that this part of the 
bioreactor can be prepared in advance. In vitro mass transfer studies were performed to 
determine the optimum operating parameters for a hollow fiber cartridge serving as a BAL. 
These studies demonstrated that cells attached to the micro carriers do not bind to the fibers, 
thereby allowing free convection of plasma/perfusion medium with an optimum cross-fiber 
pressure drop at high-flow recirculation of plasma 49. Significant metabolic support was 
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shown when cryopreserved microcarrier-attached pig hepatocytes were used in the BAL to 
treat dogs with acute liver failure continuously for 6 hours, introducing plasmapheresis to 
avoid hemolysis and platelet depletion in the perfusion system. The viability of the cells after 
6 hours of both allogeneic and xenogeneic perfusion was 90%. Unfortunately, survival was 
not one of the endpoints of this study 50. A charcoal column was added to the extracorporeal 
perfusion system before perfusion through the BAL because it was assumed that this would 
protect the porcine hepatocytes from the toxic hepatic failure plasma 51. This system, 
including plasmapheresis, charcoal column, and cryopreserved primary isolated microcarrier-
attached pig hepatocytes (approximately 4-6 x 109 ) inoculated into the extraluminal space of a 
hollow fiber cartridge, was used for the first time to treat a patient in 1993, leading to a phase 
I clinical trial with 31 patients (see Table 2). Eighteen patients with fulminant hepatic failure, 
3 patients with primary non-function after liver transplantation, and 10 patients with acute 
exacerbation of chronic liver disease were treated successfully, as indicated by significant 
neurologic improvement, decreased intracranial pressure, decreased plasma ammonia levels, 
and improvemem: of other biochemical parameters. Liver transplantation followed in 21 of the 
31 patients; the other 8 patients were not eligible for transplantation 52. 
Although this system gave promising results and a phase ll/IJI clinical trial is being prepared 
to determine efficacy, further studies are needed to establish the immunologic consequences 
of perfusing human plasma through a device containing pig hepatocytes. In addition, the 
possible transfer of viral material from the bioreactorto the host must be monitored in detail. 
Also, the long-term stable culture of human hepatocytes must be explored. Recent studies 
have shown normal proliferation of human blastocyst-derived, pluripotential embryonic stem 
cell lines, which differentiate into derivatives of all three embryonic germ layers 53. These cell 
lines could possibly b,~ used to develop noncarcinogenic human hepatocytes. When 
incorporated into a BAL, this could result in a functional device without the immunologic 
drawbacks and the potential danger of a human hepatoblastoma cell line. 
EXTRACORPOREAL WHOLE LIVER PERFUSION 
The need for hepatic tissue for effective treatment of patients with ALF led to the concept of 
using the whole liver in an extracorporeal perfusion system. Isolated liver perfusion studies 
date back to the 19th century, when they were performed to study liver metabolism, 
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demonstrating complex metabolic liver function outside the natural environment of the liver 
54 Not until 1958 was the first experimental study carried out with allogeneic livers to clear 
ammonia given to dogs. The study showed a significant decrease in ammonia levels in 
animals treated by ex vivo liver perfusion compared with control animals 55. The first clinical 
study was performed in 1965 by Eiseman et al 56, who tested several perfusion circuits in pigs 
as well as humans with ALF. During the past three decades, approximately 141 ex vivo pig 
liver perfusions have been performed to treat 87 patients with liver failure in usually poor 
clinical condition (Table 3). The technique and clinical outcome of extracorporeal whole pig 
liver perfusion, as reported in well-documented studies comprising more than one patient, are 
described below. 
Table 3. Clinical studies using extracol'pon~al pig 
liver ~erfusion 
Inycstigators Publication No. of No. of 
ycar Patients Pcrfusions 
Eiseman* 1965/1966 8 11 
Nonmm 1%7 5 13 
\Valts'" 1967 3 6 
Bertrand 1968 10 15 
Beveridge 1968 1 1 
Mieny 19G8 1 
Ham 1968 2 
Abouna* 1968/1969 4 7 
\Valts 1969 5 8 
Schleifer 1969 2 2 
Haring 1969 3 4 
Chevrel 1969/1970 4 4 
Abouna 1970 10 
Ranek* 1971 5 7 
Pharboo'" 1971 5 6 
Lempinen 1971 1 
Nic1ubO\vicz 1972/1973 5 H) 
Margulis 1975 10 10 
Tlmg* 1981 9 13 
Chari* 199..:1- 4 8 
Total: 87 141 
*Studies analyzed for Table..J-
§Kperimental set1l.P-
The pig liver has been used in most cases because it is readily available. Immediately before 
perfusion, hepatectomy is performed on pigs weighing between 20 and 45 kg. In all studies, 
the cystic duct is ligated, the common bile duct cannulated to collect the bile produced during 
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perfusion, and the hepatic artery and the portal vein are cannulated for inflow of human 
blood. The inferior vena cava is either left open, in which case outflow goes to a reservoir 
where the patient!s blood is mixed with ascitic fluid and pumped back into the circulation, or 
cannulated for immediate return of blood to the patient. The isolated liver is placed in a sterile 
perfusion chamber and connected to the patient's circulatory system within no more than 30 
minutes. Bile flow proved to be the single most reliable index of hepatic function and was 
assessed in all cases of extracorporealliver perfusion. 
Many perfusion configurations have been tested 56. In general, either blood is drawn from the 
femoral artery and returned to the patient through the saphenous vein, or a direct arterio-
venous shunt in the upper arm is used 56-58,60,61 In other studies, a veno-venous shunt was 
used, placing a double lumen catheter in the femoral vein 59 or using the femoral and jugular 
veins 62. As is known from isolated liver perfusion studies, oxygen supply to the liver is vital. 
Therefore, the addition of a heater-oxygenator unit to the perfusion system ensures a blood 
supply with a temperature of 37 to 39°C and 100% oxygen saturation. Thus, there is no 
difference in performance of the ex vivo liver between perfusing the hepatic artery and the 
portal vein or the portal vein alone 56 _ A pump is used in the perfusion circuit, either to return 
the blood from the reservoir containing 'post' -ex vivo liver blood to the patient 56.58.60,61 or to 
create stable and constant pressure and flow into the liver when a veno-venous bypass was 
used 59.62. Length of extracorporeal pig liver perfusion varied between 1.5 and 9 hours; one to 
four perfusions were performed per patient. Regional or systemic heparin was administered. 
Clinical outcome 
For the literature review, references 56 to 62 were chosen because their documentation is the 
best and the techniques used for extracorporeal pig liver perfusion are comparable. The 
variation in the cuase of the hepatic failure among individual patients from each study makes 
it hazardous to compare the success rate of the ex vivo liver perfusion technique. In addition, 
one is tempted to assume that groups of patients (e.g., those with ALF compared with those 
with chronic liver disease) may exhibit a better outcome; therefore, we determined neurologic 
improvement, the percentage decrease in levels ofNH3 or bilirubin before and after perfusion, 
as well as the mean survival (in days) to compare the results of patients with the same cause 
from the different groups. Five patients who received eight perfusions have been excluded 
because they had single-case diseases such as hepatic failure from septic shock, 
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Table 4. Patients treated with extracOi"porealliver perfusion 
Neurologic NH3 
No. of No. of Improycment Decreasc 
Cause Patients Perfusions !Perfusion (%) 
Cirrhosis 11 15 14115 55 
Viral Hepatitis 10 16 10/16 43 
Liver failur not 12 19 16/19 25 
otherwise specified 
Data from references 56-62. 
Bilirubin 
Decrease 
(%) 
36 
41 
47 
Survival 
(mean) 
4.8 days 
4.8 days + 1 
complete 
recoveI)" 
4.3 days + 2 
complete 
recoveries 
hemochromatosis, acetaminophen-intoxication, and primary graft non-function. Of the 
remaining 33 patients, ] 1 had cirrhosis from alcohol abuse, 10 had viral hepatitis, and 12 had 
hepatic failure not otherwise specified (Table 4). All patients had coma hepaticum grade IV to 
V (Table 5), and all other treatments had failed to that point. 
The results show neurologic improvement to at least coma hepaticum grade III to II in most 
patients, which does not seem to be related to the cause of the hepatic failure. Moreover, no 
relation between clearance of Ntb or bilirubin and neurologic improvement or survival and 
cause was demonstrated. This underlines the fact that the biochemical parameters used to 
describe the function of the isolated liver and to follow the clinical condition of patients with 
hepatic failure do not reveal the mechanism of hepatic failure and hepatic encephalopathy. 
Although controlled trials have not yet been carried out, the complete recovery of three 
patients and the prolonged survival of some patients strongly suggest improvement over 
conventional treatment. 
Table 5. Clinical stages of acute fulminant hepatic 
failure (Hepatic Coma) 
Grade DescJilltion Clinical symptoms 
Neurasthenic Abnormal fatigability. depression, 
syndrome confusion. altered mood of behavior, 
appropriate rcsponsc. slight tremor 
II Somnolence DrO\ysiness. inappropriate behavior. 
flapping tremor 
III Sopor Reduced responsiveness. ability to obey 
simple commands. incoherent speech. 
Babinski 
IV Coma No response to verbal stimuli, response 
to painful stimuli. decerebrate. grossly 
abnormal EEG 
V Deep coma No response to pain. little or no EEG 
actiyity 
31 
Chapler 2 
Most complications that accompany extracorporeal whole liver perfusion are due to 
preexisting cardiopulmonary disease, although hemodynamic changes during perfusion were 
highly limited. Uncontrolled bleeding secondary to thrombocytopenia as aresult of the 
oxygenator in the circuit or the development of disseminated intravascular coagulation is 
another common complication. In three patients, a relapse to stage V hepatic encephalopathy 
eventually led to death. 
Most ex vivo liver perfusion studies were performed in the late 1960s and early 1970s; the 
method was then abandoned because of the successful development of orthotopic liver 
transplantation (Table 3). However, with the present shortage of available donor organs, there 
is renewed interest in this method G2-G4 Although the results are encouraging, a controlled 
study has not yet been performed to predict conclusively the outcome of extracorporeal whole 
liver perfusion. Further, the immunologic implications of human blood perfused through 
hepatic endothelial tissue are unknown. This aspect will be considered in the next section. 
IMMUi'iOLOGICAL IMPLICA nONS 
The use of extracorporeal pig liver perfusion or an artificial liver device with pig hepatocytes 
implies contact of human blood or plasma with porcine material. ·When such an xenogeneic 
contact is established, whether it be only once or several times per patient for limited periods 
of time, immunologic problems should be anticipated. In the first clinical study on 
extracorporealliver perfusion by Eiseman et al. in 1965 56, C14_tagged glycine and lysine were 
added to the perfusion system and synthesized into protein by the pig liver that probably 
contained the porcine amino acid code, suggesting exchange of biologic material between 
graft and host. Renewed interest in the application of xenogeneic cells or tissues has drawn 
attention to the possible immunologic consequences. Although a cell-mediated reaction is 
seen at an early stage, as indicated by activation of neutrophil granuloc)rtes and natural killer 
cells after suppression of complement 65.GG, these mechanisms are probably less significant 
because therapy is intended to last only several days. For this reason, we will focus on the 
humoral response 
The humoral resp-onse 
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Xenotransplantation normally leads to hyperacute rejection of the xenograft mediated by 
preformed naturally occurring antibody (pNAb) and complement. These antibodies, also 
called xenogeneic pNAb, are directed against porcine antigens and are present in most 
primates without preceding sensitization. In man, xenoreactive pNAbs, which consist of IgG, 
IgA and mainly IgM, form 2 to 4% of the total immunoglobulins. Approximately 80% of 
these pNAbs are directed against the GAL-alpha 1,3 membrane epitope, the most important 
target antigen of the human humoral defense against porcine organs 66. pNAbs are mainly 
produced by splenic B-Iymphocytes 67, and several theories about their development have 
emerged. For instance, they may be induced by contact between mucosal immune cells and 
intestinal flora 68 or food-derived antigens with epitopes similar to GAL 69. Whether IgG, with 
a higher affinity for pig antigens, or IgM, which is supposed to act as an 'early' antibody, 
plays the predominant role in complement activation and cytotoxicity has yet to be 
established 70. In a recent study by Schraa et al 71, rats were sensitized against hamsters 1 and 
5 weeks before hepatic xenografting; high titers of IgM and IgG, respectively, were found. 
Hyperacute rejection was demonstrated in the second group but not the first group, indicating 
the importance of IgG but not IgM-mediated cytotoxicity in hepatic xenografting. As for the 
direct effect of complement, both the classical and the alternative pathways seem to be 
involved in the activation and cytotoxicity ofaxenogeneic reaction 69. 
Immunological aspects in liver perfusion 
In patients with ALF, the levels of total CH50 and C3, C4, C5, and the regulatory proteins 
factor I and beta-lH are significantly lower compared with controls 72, whereas the naturally 
occurring antibody levels do not differ. It is not clear whether this complement depletion is 
the result of impaired synthesis because of the diseased liver or ongoing activation of the 
complement system, or a combination of the two, Hyperacute rejection after xenogeneic 
kidney perfusion can be prevented only by complete inactivation of complement 73, whereas 
the perfusion of a liver with human blood is characterized by normal liver function for several 
hours 74. At the same time, the drops in the levels ofpNAbs during kidney and liver perfusion 
are similar. However, immunohistochemical analysis of the kidneys after perfusion with 
human blood demonstrates the binding of both 19M and 19G xenoantibodies and complement 
(C3) to kidney vascular endothelium, whereas staining was minimal for liver vascular 
endothelium 75. 
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Tector et al. 76 confirmed these data in an isolated liver perfusion study of blood from patients 
with liver failure. They showed significantly reduced complement levels and activity 
compared with normal subjects, resulting in an impaired ability to lyse both aortic and 
sinusoidal endothelial cells. Immunofluorescent analysis showed little or no staining for 
sinusoidal deposition of IgM, IgG or C3, suggesting that the sinusoidal endothelium of the 
liver can remove antibody and complement without cell lysis, possibly by endocytosis, 
compared with aortic or other endothelium. 
Tabel 6. STRATEGTES TO 
HYPERACUTE REJECTION 
HUMAN XENOGRAFTS 
Antibody 
OVERCOME 
OF PIG-TO-
• Removal by plasmapheresis, immlUloapheresis 
Remoyal by absorbtion \\·ith pig organs 
Remoyal by absorbtion on gal columns 
Block \vitll high avidity chicken anti-gal 
Block \vith peptides 
Antigen 
• Gene "knock ouC (not in pig) 
• Anti-sense constructs 
• Enzymatic destruction: External Galactosidase transgcne 
Suppress GAL: H transferase transgene 
• Secretor gene 
Complement 
• Cobra venom factor 
e Antibodies 
Solu1e complement receptor receptor type 1 
• Twnsgenes (CD46[MCP1. CD55[DAF1. CD59) 
Adapted from McKenzie et al 79 
The same results were obtained in a clinical study in which no adverse effects on ex vivo 
organ function were measured during treatment of patients with ALF by extracorporeal pig 
liver perfusion. Again, low complement levels, normal amounts of pNAbs, and, after 
perfusion, only trace deposits of pNAb and C3 on the sinusoidal endothelium with a decrease 
in the level ofpNAb were demonstrated 77. Long-term follow-up of these patients showed an 
increase in xenoreactive IgM and IgG within 10 days of perfusion and a subsequent return to 
normal 78. These concepts are being used to study ways to delay hyperacute rejection (Table 
6) 79. Several strategies are being tested in different organs, with encouraging results. The 
efficacy of humoral mediators present in serum has been reduced by means of porcine livers 
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transgenic for human decay-accelerating factor (DAF/CD55) 80, Reduced humoral injury was 
found with soluble complement receptor type 1 Xl, and immunopheresis was successfully used 
to remove xenogeneic pNAb before peIil.lsion of the liver, which resulted in improved 
functioning of the perfused liver 1.:2. 
The role of the immunologic defense in the treatment of patients with liver failure is far from 
clear, but no immunologic adverse reactions have been detected during treatment in the 
clinical studies reported thus far. In one patient with chronic aggressive hepatitis who 
underwent] 6 extracorporeal liver perfusions in 2.5 months, a decrease in antibodies could be 
shown after every perfusion. This was followed by a progressive rise in the titer of these 
antibodies, which peaked during the fifth perfusion, when an anaphylacic reaction was 
recorded; the next five perfusions with a pig liver did not cause detrimental effects 83. 
Whether prolonged or repetitive treatment leads to sensitization of the patient to porcine 
antigens remains to be determined. 
Immunological aspects of artificial liver devices 
Compared to extracorporeal whole liver perfusion, where human blood is in direct contact 
with porcine liver endothelium, artificial liver systems contain only pig hepatocytes and are 
usually perfused with human plasma, because a plasma separation unit is used in the 
perfusion circuit. As described before, the hollow fiber bioreactor consists of several 
compartments that communicate through the pores in the fiber walls, allowing mass transfer 
between the patient's plasma and the heterologous hepatocytes. The size of the pores is 
determined by the balance between sufficient waste removal and potential immune activation. 
Removal of ammonia, aromatic amino acids, and red blood cell breakdown products such as 
bilirubin (MW 0.6 kDa) is desirable. Coagulation proteins such as prothrombin (MW 70 kDa) 
and thrombin (MW 40 kDa) could potentially benefit the patient, which is why they should be 
allowed to pass through the fiber membrane. However, immunoglobulins (l\.1\V 150-900 kDa) 
and cytokines (MW 100-400 kDa) preferably do not make contact with the hepatocytes. The 
ideal molecular weight cutoff therefore may lie between 50 and 100 kDa 35, which should 
theoretically prevent a cellular as well as a humoral immune response. 
However, te Velde et al. 84 showed that rats infused with the supernatant of in vitro cultured 
pig hepatocytes raised antibodies against the very small amounts of pig hepatocyte-derived 
proteins in the culture medium. Another study showed an increase in tumor necrosis factor-
alpha after a 4-day perfusion of pigs connected to a hybrid liver support system containing 
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homologous hepatocytes 85, although no typical side effects were observed. In a clinical study 
on patients with ALF treated with the BAL, anti-pig xenoantibodies (lgM and IgG) remained 
at the same level 10 days after treatment, when one treatment was carried out. If more than 
one treatment was given, the levels increased two to threefold and decreased only if 
immunosuppression was administered because of subsequent liver transplantation. 86. Thus, 
either through contact of human plasma with the pig hepatocytes during perfusion or because 
of pig hepatocyte material entering the human circulation, an immunological reaction can be 
induced. Whether this is of clinical relevance remains to be seen, since so far no side effects 
have been noticed. 
Cellular and humoral graft-versus-host reactions also must be considered, although thus far 
there is no proof of this type of reaction in the literature. In a baboon-to-human liver 
transplantation, no baboon antibodies were detected in the human serum 87. Another problem 
is the potential risk of zoonosis. Patience et al 88 showed that porcine kidney cell lines release 
particles of pig endogenous retrovirus (PERV), which can infect human cell lines in vitro. 
However, transmission of PER V from transplanted porcine endothelial cells to baboons 89 or 
humans 90 in vivo has not been detected. Obviously, these issues need further attention if 
artificial liver systems are to be used in clinical trials. 
CONCLUDL'IG REMARKS 
Two major concerns are noted in the literature on extracorporeal liver perfusion for the 
treatment of liver failure. First, there is still no clear understanding of the biologic 
mechanisms of liver failure; therefore, the various approaches to temporary treatment of this 
disease lack a well-defined basis. Second, no uniform definition of liver failure is given. 
Within studies and between studies, there is a wide variety in the severity of liver disease, and 
success of treatment is defined in many ways. Although most studies report temporary 
improvement of the patient's clinical neurologic condition, evidence-based research indicating 
successful treatment has not yet been reported. Therefore, in our opinion, randomized studies 
that focus on a well-defined method and include sufficient patients to allow adequate 
statistical analysis are needed to determine the efficacy of this approach. Only then can 
conclusive evidence be gathered to benefit patients with liver failure who undergo either 
extracorporeal whole liver perfusion or treatment with a BAL. 
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ABSTRACT 
The successful development of a bioartiflcial liver relies, in part, on the ability to maintain 
viability and differentiated function of a large number of hepatocytes in vitro for extended 
periods of time. Microcarriers have been widely used to scale up anchorage-dependent 
mammalian cell cultures. The goal of the present study was to seek optimal culture conditions 
for hepatocytes attached to microcarriers. Hepatocytes were seeded onto gelatin-coated 
polystyrene microcarriers, and the composite was cultured in suspension or embedded in an 
agarose or type I collagen gel for up to 14 days. We were able to seed up to 130 hepatocytes 
per micro carrier. Viability and function of hepatocytes on micro carriers cultured in 
suspension or in agarose decreased as a function of time. On the other hand, microcarriers 
embedded in a collagen gel exhibited specific albumin and urea secretion rates of 
approximately 3 ).lglhJ106 cells and 10 ,uglhJ I 06 cells during the second week of culture, 
respectively. These rates were similar to those obtained in control cultures of col1agen-
sandwiched hepatocytes in the absence of microcarriers, Thus, long-term liver-specific 
function can be induced by surrounding hepatocytes seeded on microcarriers with a collagen 
gel. This may be a viable approach to scale up the sandwich hepatocyte culture system. 
INTRODUCTION 
A promising approach for the treatment of hepatic failure is the use of an extracorporeal 
bioartificial liver device containing xenogeneic hepatocytes. Critical to the successful 
development of this technology is the ability to foster long-term viability and function of a 
large cell mass (~1 0% of liver) since freshly isolated hepatocytes take as much as 1 week in 
culture to fully re-express differentiated functions, and long treatement periods (days to 
weeks) are anticipated. Current systems being evaluated include rat or pig hepatocytes 
entrapped in hollow fiber devices, cultured on flat plates, cultured on rnicrocarries, or 
combinations thereof 1-7. The level of expression of liver-specific function in these large-scale 
systems is often lower than that observed under optimal conditions in small-scale cultures. 
Potential explanations include (a) nutrient transport limitations, (b) a microenvironment that 
Hepatocyle culture olllllicrocarriers 
does not induce hepatocyte differentiation, and (c) insufficient time in culture to allow full 
recovery of the expression of liver-specific function after hepatocyte isolation. 
Long-term viability and function of hepatocytes can be induced by (a) specific medium 
formulations 5." (b) complex extracellular matrices 10, (c) feeder cell layers lLl2, (d) culture as 
aggregates or spheroids 6,13 and (e) culture in collagen gels 14-17. In the latter approach, cells 
can be either directly suspended in a type I collagen gel or "sandwiched" by placing a 
collagen gel overlay on top of a monolayer of hepatocytes preseeded onto another collagen 
layer 14.17. Culture in collagen gels is an attractive option that is suitable for scaleup and 
eventual use as the basis for a bioartificial liver for several reasons. First, a physiologically 
compatible medium can be used. Second, no complex, poorly defined, or expensive 
extracellular matrix materials are required. Third, the cumbersome task of propagating a 
feeder cell line is obviated. Finally, hepatocytes sandwiched in type I collagen adopt a 
monolayer morphology, which facilitates the optimization and control of nutrient and 
metabolic transport between the cells and the medium. However, the sandwich culture system 
in its current form is not easily amenable to scaleup because it requires a flat surface to lay 
down the collagen layers. Scaleup of cultures with a flat-plate geometry is cumbersome and 
has previously yielded relatively low cell concentrations (-....0.5 x 106 cells/ml) 2. 
Microcarriers have been widely used for scaling up mammalian cell culture and provide a 
large biocompatible surface area per unit volume. In addition, sampling of the cells from the 
culture is possible, which facilitates characterization of a large-scale culture system under 
development. Microcarriers seeded with hepatocytes have been used in suspension, in a 
perfused packed-bed system as well as packed in the extraluminal (or shell) compartment of 
hollow fiber modules 3,4.18. In these cases, liver-specific function was evaluated on a short-
term basis « 70 h). In one study, Shnyra et al 19 examined hepatOCyte function on 
microcarriers cultured in suspension over 1 week. They observed a stable phase of albumin 
secretion for up to 5 days followed by a decrease, with a concomitant increase in fibronectin 
secretion. Similar findings were made with hepatocytes cultured in plastic dishes or on a 
single collagen gel and are indicative of dedifferentiation 10,14.20 In these systems, the 
necessary microenvironment to induce and maintain liver-specific function was not provided. 
In the current investigation, we sought to establish long-term function of hepatocytes on 
microcarriers. Thus, we examined the effect of embedding rnicrocarrier-attached hepatocytes 
in a collagen gel, thereby creating a sandwich configuration between the microcarrier surface 
and the surrounding collagen, on the morphology and expresion of two major liver-specific 
functions (albumin and urea synthesis) by hepatocytes. 
45 
Chapter 3 
MATERIALS AND METHODS 
Materials 
Dulbecco's modified Eagle medium (DMEM) with 4.5 gil glucose was purchased from Gibco 
(Gaithersburg, MD, USA); fetal bovine serum (FBS), penicillin, and streptomycin from 
Hazleton (Lenexa, KS, USA); hydrocortisone from Upjohn (Kalamazoo, MI, USA); 
epidermal growth factor (EGF) from Collaborative Research (Bedford, CA, USA); and 
insulin from Squibb (Princeton, NJ, USA). Seaplaque low gelling temperature agarose (for a 
1 % w/v agarose gel, the gelling temperature is 26-30°C and the melting temperature is 65°C) 
was obtained from FMC Bioproducts (Rockland, ME, USA). Type I collagen (1.2 mglml in I 
rn1vf HCI) was prepared from rat tail tendons as described previously 16. Calein acetoxymethyl 
ester (Calcein AM) and Hoechst 33258 were obtained from Molecular Probes (Eugene, OR, 
USA). Cytodex 2 and Cytodex 3 microcarriers were obtained from Pharmacia (Piscataway, 
NJ, USA) and gelatin coated plastic microcarriers (cat. no. M-9650) from Sigma (St. Louis, 
MO, USA). All other chemicals, including calf thymus DNA (cat. no. D-5668), were obtained 
from Sigma (St. Louis, MO, USA). 
The culture medium consists ofD:rvtEM supplemented with 10% PBS, 200 units/m! penicillin, 
200 flglml streptomycin, 50 flglml gentamycin, 20 nglml EGF, 7.5 flglml hydrocortisone, 20 
nglml glucagon, and 0.5 unit/m! insulin. SDS buffer consists of 0.1 % w/v sodium dodecy! 
sulfate and 1 llli\1 ehtylenediamine tetraacetic acid (EDTA) in 100 mM Tris-HCI (pH 7.4). 
TEN buffer consists of 10 llli\1 Tris-HCI (pH 7.4) with 1 mM EDTA and 2 M NaCL 
Isolation of hepatocytes 
Hepatocytes were isolated from 2- to 3-month-old female Lewis rats (Charles River 
Laboratories, Boston, MA, USA) by a modified procedure of Seglen 21 Details of the 
isolation procedure are described elsewhere 16. The average yield was 200-250 x 106 
hepatocytes with a viability of 80-90% as determined by trypan blue staining. 
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Microcarrier Preparation and Characterization 
Plastic microcarriers were suspended in 50 ml of culture medium and allowed to sit overnight 
at 4°C. The concentration of microcarriers was determined by placing aliquots of appropriate 
dilutions of the stock suspension in a 96-well plate and counting the number of microcarriers 
per well using a stereoscope (Nikon S1v1Z 2B). This stock solution was kept at 4°C until use 
for a maximum of2 months. 
To detennine the microcarrier size and distribution, microcarriers were visualized through a 
Plan Neofluar 10xlOJO NA objective on a Zeiss Axiovert 10 inverted microscope (Zeiss, 
Thornwood, NY, USA) equipped with a Nuvicon camera (Hamamatsu, Japan). Phase contrast 
images were acquired and digitized using Image/1 software (Universal Imaging Inc., West 
Chester, P A, USA) installed on a 486/66 MHz IBM compatible personal computer, recorded 
on an optical laser disc, and trasnferred onto Kodak Tmax 100 35-mm film using a LFR+ film 
recorder (Lasergraphics, Irvine, CA, USA). The diameter of at least 100 microcarriers was 
measured on printed images. The length scale was determined form images of a 
hematocytometer grid processed in an identical fashion. The average microcarrier diameter 
was found to be 163 ± 19 ).lm. Thus, the average surface area of a microcarrier, calculated 
assuming spherical geometry, is 8.3 x 104 ).lm2. 
Hepatocyte Attachment Procedure 
T25 square flasks (Corning Glassware, Corning, NY, USA) were made nonadherent by 
incubating them overnight with 5 ml of 0.1 % w/v bovine serum albumin (BSA) in phosphate 
buffered saline (PBS) at 37"C. The flasks were rinsed with PBS three times, and 5 x 104 
microcarriers and 2.5-10 x 106 viable hepatocytes (i.e., 50-200 cells per microcarrier) 
suspended in 5 ml of culture medium were added. The flasks were gassed for 2 min with 10% 
CO, + 90% oxygen (Northeast Airgas, Nashua, NH, USA), closed thight, placed on a linear 
shaker (New Brunswick Scientific, Edison, NJ, USA) at 37"C, and subjected to a 5-sec 
shaking cycle (amplitude: 1 in., speed: 150 rpm) every 5 min for 24 h. Based on our previous 
experience with seeding hepatocytes onto microcarriers, a high oxygen concentration in the 
gas phase and intermittent shaking are optimal for cell attachment 23, To seperate unattached 
cells from hepatocytes attached to microcarriers, the total content of each T25 flask was 
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filtered through a nylon filter (mesh size 100 11m), and the retained microcarriers with 
attached hepatocytes were used in the subsequent procedures. 
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Figure 1. Number of cells per microcanier before and after long-term cultUre in collagen, agarose, or 
in suspension. Cells were seeded onto plastic microcarriers using a celUmicrocarrier ratios of 50: 1 to 
200: 1. The amount of microcarrier-bound DNA normalized to the number of microcarriers was 
detennined after seeding (solid bars) and after culture bet\veen two layers of collagen gel, agarose gel, 
or in suspension in agarose-coated dishes for 14 days (shaded bars). The amount of DNA is expressed 
as a cell number based on DNA standards containing knovm concentrations of freshly isolated 
hepatocytes. Each data point shovm is the average of at least three replicate dishes. NS "'" not 
statistically significantly different. 
To estimate the number of attached cells per microcarrier, the filtered microcarriers from each 
flask were resuspended in 4 ml of SDS buffer, and the samples were incubated overnight at 
37°C. Total DNA was measured using a method described elsewhere 22. Briefly, 40 )11 of the 
sample were added 102 ml of a Hoechst 33258 dye solution (0.1 I1g/ml ofHoechst 33258 in 
TEN buffer), and the fluorescence (settings: excitation, 365 nm; emission, 458 nm) was 
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measured in a SPF 500C spectrofluorometer (SLM Instruments, Urbana, IL, USA), DNA 
standards consisted of solutions containing known concentrations of calf thymus DNA (0-50 
~g/ml in SDS buffer). The resulting amount of DNA was converted to a cell number using an 
appropriate standard curve prepared using cell suspensions containing 0-2 x 106 cells/ml of 
freshly isolated hepatocytes in SDS buffer On the average, the specific DNA content of 
freshly isolated hepatoyctes was 25.4 ± 39 ~g DNNI06 cells. The cell number was then 
divided by the total number of microcarriers in each sample. 
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Figure 2. Effect of extracellular matrix composition on albumin secretion of hepatocytes cultured on 
microcarriers. Hepatoc~-1es were seeded onto plastic microcarriers using a celllmicrocarrier ratio of 
100:1. The microcarriers \vere cultured in suspension in 100-mm dishes 05,000 ± 900 
microcarriers/dish), or embedded between two gels of agarose or collagen in 60-mm dishes (3,700 ± 
300 microcarriers/dish). Specific albumin secretion rates were calculated by multiplying the albumin 
concentration values by the volume of daily medium change (5 mL for suspension cultures, 2 mL for 
the others) and normalizing to the the number of microcarriers in the dish and the sampling time (1 
day). Each data point shown is the average of at least three replicate dishes. 
Long-Term Culture afHepatocytes on Microcarriers 
The microcarrier-attached hepatocytes were cultured in three different ways: (a) in suspension 
in medium on top of an agarose gel, (b) embedded in agarose, and ( c) embedded in type I 
49 
Chapter 3 
collagen. For each suspendion culture, the content of one T25 used for seeding was filtered, 
the retained microcarrier cells resuspended in 10 ml of culture medium, and then spread into a 
IOO-mm bacterial Petri dish precoated with an agarose gel. The coating was prepared by 
pouring 3 ml of an agarose solution (prepared by dissolving 1 % w/v agarose powder in PBS 
at 90-IOO°C) into each dish followed by incubation at 4°C for 30 min. Every day, 5 ml of 
medium were replaced with fresh medium. 
For the cultures embedded in agarose or collagen, 60-mm dishes were precoated with 1 ml of 
a 1% agarose gel (prepared as above) or 0.1% collagen gel, respectively. The collagen gel was 
prepared by mixing 9 parts of a coBagen stock solution (1.2 mg/ml in I rnM HCl) with 1 part 
of serum-free lOx Dl\1EM on ice. One milliliter of this solution was poured into each dish, 
and gelation was induced by incubating at 37°C for 30 min. The contents of a T25 flask used 
for seeding microcarriers was filtered, and the retained microcarrier cells resuspended in 8 ml 
of culture medium. Two milliliters of this suspension were added per agarose- or collagen-
coated 60-mm dish. This yields ~3,700 microcarriers/dish, the standard seeding density used; 
larger or smaller densities were obtained by adding a proportionally greater or smaller amount 
of microcarrier cell suspension. These cultures were incubated overnight at 37°C, and, after 
aspirating the culture medium, they were overlaid with 1 ml of either liquid 1 % agarose in 
PBS at 3rC or a collagen solution. Gelation of the agarose and collagen overlays was 
induced by placing the cultures at 4°C or 37°C for 30 min, respectively, prior to adding 2 m! 
of fresh culture medium per dish. 
Control cultures conisted of 2 x 106 viable hepatocytes seeded between two !-m1 collagen 
gels as descreibed previously 16. All cultures were kept at 37°C in a humidified atmosphere 
with 10% C02, balance air. Culture medium was replaced daily. Medium samples were saved 
every other day for albumin and urea level determination. 
To estimate the number of viable cells remainng at the end of the culture period (14 days), the 
amount of DNA per dish was determined. Suspended cultures were removed from the dishes, 
washed in PBS, and resuspended in 4 ml of SDS buffer. To liberate cells from collagen-
embedded cultures, the medium was removed, and the dishes were rinsed with PBS and 1 ml 
of 0.1 % collagenase in Krebs-Ringer buffer supplemented with 0.2 mg/ml CaCho After 15 
min at 37°C, the freed cells were removed, washed in PBS, and resuspended in 4 ml of SDS 
buffer. To liberate cells from agarose-embedded cultures, agarose was liquefied by heating 
the cultures to 65 c C. The cells were removed, washed in PBS, and resuspended in 4 ml of 
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SDS buffer. The amount of DNA in each sample was determined and the corresponding 
number of viable cells calculated as described previously. 
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Figure 3. Effect of number of cells seeded per microcarrier on albumin secretion by hepatocytes. 
Hepatocytes were seeded 011to plastic microearriers using eeIVmicrocarrier ratios of 50:1 to 200: 1. 
The microcarriers were embedded bet\veen t,,\'o gels of collagen in 60 mm dishes (3,700 ± 270 
microcarriers/dish), and the culture medium was changed daily (2 mUd). Each data point shown is the 
average of at least three replicate dishes. 
Albumin and Urea assays 
Albumin concentration in medium samples was measured using an enzyme-linked 
immunosorbent assay in 96-well plates using purified rat albumin standards (0-100 !-lglml) 
and a peroxidase-conjugated anti-rat albumin antibody (sheep IgG) that does not cross-react 
with BSA (cat #55776, Cappel, Cochranville, PA, USA). The absorbance was measured with 
a Dynatech IVlR600 microplate reader (Chantilly, V A, USA). Urea concentrations were 
assayed using an assay kit (Sigma Chemical, St. Louis, MO, USA; cat no. 535-A). Albumin 
and urea concentration measurements were converted into specific secretion rates (either per 
microcarrier or per cell). 
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Viability Staining 
At the beginning (day 2) and at the end (day 14) of the culture period, some cultures were 
stained using the viability dye ca1cein AM. Ca1cein AM: specifically labels viable cells with a 
green fluorescence while nonviable cells remain nonfluorescent. Ca1cein AM: was added to 
the culture medium to a final concentration of 1 !J.M and the dishes incubated at 37°C for 3 
min. The stained cultures were visualized through an Achrostigmat 20xlO.30 NA objective on 
a Zeiss Axiovert 10 inverted microscope. A mercury lamp and standard fluorescein optics 
were used for observation of calcein fluorescence. Images were acquired, digitized, and 
transferred onto film as described previously. 
Statistical Analysis 
Analysis of variance was used. Statistical significance between groups was determined by the 
Tukey Honest Significant Difference Test for unequal sample sizes. The level of statistical 
significance was set to p < 0.05. Data shown are the average ± SEM unless othervvise 
specified. 
RESULTS 
Attachment and Viability of Hepatocytes on Microcarriers 
To determine the maximum number of cells that could be attached onto microcarriers, 
hepatocytes were seeded with cell/microcarrier ratios of 50: 1 to 200: 1. DNA analysis of 
microcarriers after seeding shows a saturation coverage at approximately 130 
cells/microcarrier (Fig. 1). Furthermore, viability was preserved after 14 days of culture in 
collagen, based on the amount of DNA remaining at that time. In contrast, cultures of 
microcarriers seeded with a cell/microcarrier ratio of 100:1 and maintained in suspension 
retained less than 10% of the initial amount of DNA. Because suspended microcarrier cultures 
formed large aggregates wherein nutrient transport limitations may occur, microcarriers were 
also immobilized in agarose. Again, the amount of remaining DNA after 14 days was less 
than 10%, suggesting a specific requirement for collagen to maintain hepatocyte viability. 
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Figure 4. Effect of number of microcarriers per dish on albumin secretion by hepatocytes. 
Hepatocytes ,",'ere seeded onto microcarriers using a cell to microcarrier ratio of 100: 1. The 
microcarriers \vere embedded between two gels of collagen in 60 nun dishes, and the culture medium 
was changed daily (2 mIld). Each data point shov.'Il is the average of at least three replicate dishes. 
Expression oj Liver-Specific Functions 
To investigate the effect of the culture conditions with respect to the expression of liver-
specific function, albumin secretion rates were determined (Fig. 2). In collagen-sandwiched 
microcarriers, the albumin secretion rates increased approximately 7-fold between days 2 and 
8 and were relatively stable at 3-4 nglmc/d from days 8 to 14. Microcarriers cultured in 
suspension or embedded in agarose exhibited albumin secretion rates below 0.5 nglmc/d after 
day 6. Thus, long-term albumin secretion levels (i.e., at day 6 of culture and afterwards) 
paralleled the DNA data obtained earlier 
To optimize the culture conditions in collagen and to ensure that no significant nutrient 
limitations were present, the seeding density was varied in two ways. First, microcarriers were 
seeded with ceillmicrocarrier ratios of 50: 1 to 200: 1. The albumin secretion rate per 
microcarrier increased as a function of seeding density (Fig. 3). No further increase in 
function was observed above a seeding ratio of 150 hepatocytes/microcarrier, consistent with 
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the maximum number of cells that could be attached to each microcarrier. Second, 
microcarriers were plated between 3,300 and 54,500 microcarriers per 6-mm dish, keeping the 
cell/microcarrier ratio constant at 100: L Increasing the total numer of microcarriers up to 
12,000 IPicrocarners per dish did not affect the albumin secretion rate per microcarrier, but a 
significant reduction was observed at 25,000 and 54,500 mc/dish (Fig. 4). These densities 
correspond to 2.5 and 5.5 x 106 cells/dish. We have observed a similar reduction in albumin 
secretion in standard sandwiched hepatocyte cultures above a seeding density of 2 x 106 cells 
per 60-mrn dish (unpublished observations), suggesting that this effect is not due to the 
presence of microcarriers but may arise due to possible nutrient limitations. 
The function of hepatocytes on microcarriers was compared with the previously established 
sandwich culture system. Hepatocytes were seeded onto microcarriers and cultured in the 
collagen sandwich in parallel with hepatocytes directly placed in the collagen sandwich in the 
absence of microcarriers. Specific albumin and urea secretion rates of hepatocytes on 
microcarriers, expressed on a per-cell basis, were approximately 3.0 ]...lg albumin/hll06 cells 
and 9.5 !l-g urea/hJl06 cells in the second week of culture, and were similar to that of 
hepatocytes in the absence of micro carriers throughout the course of the experiment (Fig. 5). 
MOIphology and Spatial Localization oj Hepatocytes on Microcarriers 
To confirm our viability results and to assess the morphology ofhepatocytes after embedding, 
microcarrier-hepatocyte cultures embedded in agarose or collagen were visualized by phase 
contrast microscopy and stained with the viability marker calcein Al\.1. Two hours after 
placing the second gel layer (day 2 after isolation), agarose-embedded microcarriers bear 
viable cells over much of their surface (Fig. 6, panels A & C). On day 14, cells on agarose-
embedded microcarriers still appear to be evenly distributed. There is little calcein 
fluorescence, however, suggesting a considerable loss of cell viability (panels E & G). On day 
2, microcarriers embedded in collagen show a tendency to spread away from the microcarrier 
surface (panels B & D). On day 14 of the culture, hepatocytes have formed a belt that appears 
to be located approximately halfway through the microcarrier as determined by focal plane. 
The bright ca1cein fluorescence suggests that many of these cells are alive (panels F & H). 
Similar findings were obtained even if the overlay was placed as early as 2 h after plating the 
microcarriers (not shown) 
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Figure 5. Comparison of liver-specific functions between hepatocytes cultured on microcarriers 
embedded in collagen and hepatocytes embedded in collagen in the absence of microcarriers. 
Hepatocytes were seeded onto microcarriers using a cell to microcarrier ratio of 100: 1. The 
microcarriers \vere embedded between two gels of collagen in 60-mm dishes (3,460 ± 860 
microcarriers/dish). In addition, freshly isolated hepatocytes were seeded at 2 x 106 cells per 60-rum 
dish and cultured between two gels of collagen. The culture medium was changed daily (2 mUd). 
Secretion rates for albumin (panel A) and urea (panel B) were nonnalized to the number of cells 
(based on the DNA content) per dish at the end of the culture (14 days post seeding). Each data point 
shown is the average of at least nine replicate dishes. 
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DISCUSSION 
Microcarriers have been used previously for large-scale culture of hepatocytes; however, 
long-term and stable expression of liver-specific function had not been demonstrated before. 
Furthermore, it was not possible to determine whether cell viability and function were 
compromised due to nutrient limitations or to an inherent inability of hepatocytes to function 
on microcarrier surfaces. In this study, we assessed the potential of microcarriers to serve as 
attachment surfaces for future large-scale hepatocyte culture systems by optimizing the 
seeding and culture of hepatocytes on microcarriers. Liver-specific function was induced by 
embedding the hepatocytes attached to microcarriers in a collagen gel, thereby sandwiching 
the hepatocytes between the microcarrier surface and the surrounding collagen. In the absence 
of significant transport limitations, we show that these hepatocytes exhibit a high level of 
albumin and urea secretion for at least 14 days in culture. 
We were able to seed approximately 130 hepatocytes per microcarrier, which corresponds to a 
seeding density of 1.6 x 105 cells/cm2 of bead surface. In our experience, the maximal cell 
coverage in collagen-coated dishes corresponds to 2 x 105 cells/cm2, suggesting that 
approximately 80% coverage of the microcarriers surface was obtained in the current studies. 
Microcarriers examined in the seeding flasks appeared to be entirely covered with cells, while 
those that were transferred to the culture dishes often exhibit bare spots. Foy et al 23 
previously suggested that cells may be subjected to significant detachment forces during 
postseeding manipulations (e.g. pipetting, filtration) that may limit the ultimate seeding 
density on microcarriers. Thus, coverage approaching 100% may be possible if more gentle 
postseeding manipulations are used. Using microcarriers made of cross-linked dextran coated 
with denatured collagen (Cytodex 3, diameter = 133-215 ~m), Foy et al 23 could seed no more 
than 100 cells per microcarrier, which corresponds to a seeding density of 1.2 x 105 cells/cm2 
of bead surface. In a preliminary evaluation of different microcarriers, we found that 
hepatocytes seeded on gelatin-coated polystyrene microcarriers and cultured for 14 days in 
suspension remained evenly distributed around the polystyrene microcarriers. Hepatocytes 
seeded onto Cytodex 3 inititally attached and spread somewhat but eventually detached to 
form aggregates (unplubished observations). This finding is consistent with prior studies 
suggesting that denatured collagen, by virtue of its lack of rigidity, is not conductive to 
hepatoyte spreading and instead, promotes aggregate formation 24. On the other hand, the 
plastic surface does not yield to cell-generated forces an thus allows cells to spread. Because 
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AGAROSE COLLAGEN 
DAY 2 
DAY 14 
Figure 6. Morphology and distribution of hepatocytes cultured on microcamers embedded in agarose 
and collagen gels. Hepatocytes were seeded onto plastic microcarriers using a celIJmicrocarrier ratio 
of 100: 1 and embedded bet\\,'een two agarose or collagen gels. The cells ,-vere stained with calcein 
AM 2 h after placing the second gel (day 2 after hepatocyte isolation) as \vel! as after 14 days in 
culture and visualized. Panels A, B, E, and F are phase contrast images. Panels C, D, G, and H show 
the corresponding calcein fluorescence distribution. 
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cell spreading is generally required for strong attachment to the substrate, it is possible that 
cell loss is less likely to occur during handling of pi as tic rather than Cytodex 3 microcarriers. 
Albumin and urea secretion were evaluated a<; two major representative liver-specific 
functions. Albumin secretion was used as a marker for protein synthesis because it requires 
liver-specific gene expression and intact translational and secretory pathways in the cell 25. 
Both cultures on micro carriers embedded in collagen and control sandwich cultures exhibited 
a time-dependant increase in the rate of albumin secretion during the first week to remain 
stable thereafter. A similar behavior has been observed in various long-term culture systems, 
and it has been suggested that this dynamic behavior reflects the repair and recovery process 
that hepatocytes must undergo after isolation 14,16. The albumin secretion rate in the second 
week of culture (approximately 3 ~g albumin/hlIO' cells) falls within the range reported for 
other optimal long-term hepatocyte culture systems (1-10 ~g albumin/hll06 cells) 9,10,12,15,16 
and compares well with the in vivo rate of -7 ).lg albuminlh/106 cells 16,26. Suspended cultures 
or agarose-embedded cultures did not exhibit a sustained upregulation of albumin secretion. 
This trend has also been observed in spinner flask cultures of hepatocytes on Siosilon 
microcarriers 19. The low level of albumin secretion obtained in these cases is consistent with 
the previous observations that hepatocytes cultured on a single surface (either tissue culture 
plastic or a single collagen gel) and hepatocytes overlaid with an agarose gel exhibit low 
albumin secretion rates in long-term cultures 10,16,20. Overall, these data suggest that a 
surrounding collagen matrix was required for hepatocyte differentiation on microcarriers and 
that hepatocytes are functionally similar on these surfaces as in standard cultures in the 
collagen gel sandwich. This conclusion does not hold solely with respect to albumin secretion 
since urea secretion in cultures of microcarrier-attached hepatocytes in collagen, used as a 
marker of detoxification functions, was similar to that in the control sandwich cultures. 
One interesting observation is that, after embedding, hepatocytes appeared to extend 
progressively into the surrounding collagen on a plane approximately halfway through the 
microcarrier when placed on top of a collagen gel. Hepatocyte aggregates have been shown to 
dissociate into individual cells when placed on a collagen gel 13. This behavior may indicate a 
higher affinity of the cells for the collagen matrix as opposed to the microcarrier surface or 
other cells. We were unable to prevent this phenomenon even if microcarriers were directly 
suspended in a collagen solution or when the second gel added after a shorter period of time 
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(unpublished observations). Hepatocyte migration always occurred in a plane parallel to the 
surface of the dish, suggesting that certain macrosocopic features of the gel (e.g. geometry, 
attachment to the bottom plastic surface) may import some directionality to this process. 
Current approaches for the development of bioartificial liver devices using primary 
hepatocytes involve microcarrier-attached hepatocytes 3,4, hepatocytes embedded in a 
collagen gel within hollow fibers L7, hepatocyte aggregates 6, and hepatocytes sandwiched 
between collagen layers on parallel plates 2. In these systems, hepatocytes are introduced in 
the unit shortly after isolation, and the performance of the device is measured over a period of 
a week or less. This period of time corresponds to that normally required for the functional 
recovery of hepatocytes after isolation 25. Nutrient limitations and the lack of an appropriate 
microenvironment conductive for hepatocyte differentiation may also explain the poor 
functional results obtained in some of these systems. One potential approach to facilitate the 
development of large-scale hepatocyte culture systems is to allow hepatocyte differentation 
and recovery from the isolation procedure prior to introduction into a large-scale device. The 
availability of fully functional and differentiated hepatocytes would facilitate the optimization 
of bioreactor performance with respect to providing an adequate nutrient supply. 
Microcarriers may provide a convenient scaleable unit for the devolopment of large-scale 
hepatocyte culture systems. Although in the current studies the microcarriers were embedded 
in a collagen gel, the next step would likely involve placing a thin collagen layer around each 
microcarrier. These microcarriers could then be cultured in suspension in a well controlled 
homogeneous environment to allow sufficient time for the re-expression of differentiated 
function. Furthermore, microcarrier-attached hepatocytes can be stored frozen until needed. 
The survival of cultured hepatocytes to a freeze-thaw cycle is significantly enhanced 
compared with freshly isolated hepatocytes 27, and hepatocytes have been successfully 
cryopreserved on microcarriers 4. Cell survival after freeze-thaw requires precise control of 
cooling and warming rates, which may not be possible over the length scales of large devices 
(mm to em), 
Potential formats for a bioartificial liver based on microcarriers are packed or fluidized 
systems, or incorporation into hollow-fiber devices. The minimum cell mass required for a 
bioartificial liver has been estimated to be approximately 10% that of the intact human liver 
28. Assuming that each microcarrier with 130 cells occupies a 250 )lm x 250 )...lm x 250 )lm 
volume in a bioreactor, the resulting cell density is ...... 107 cells/cm3, and thus the total volume 
required to accommodate the target number of 1010 cells would be about 1 liter. Assuming 
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that the void volume of the reactor would be of the same order of magnitude, it would be 
significantly larger than commonly used extracorporeal devices such as kidney dialysis 
equipment (90-250 ml) 29. However, the use of smaller microcarriers could eventually bring 
this volume down. 
In conclusion, we have found that hepatocytes cultured on gelatin-coated plastic microcarriers 
and embedded in type I collagen secrete albumin and urea at rates comparable to that seen in 
small-scale long-term culture systems. In addition, the specific albumin secretion rate 
obtained was similar to that found in vivu. These findings suggest that rnicrocarriers might be 
useful in the development of a large-scale hepatocyte culture system expressing high and 
stable levels of liver-specific function. 
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ABSTRACT 
Background At present, transgenic pig livers are being used to study the feasibility of 
extracorporeal liver support in the management of acute liver failure. However, it remains to 
be determined whether non-immunological aspects may limit the quality of extracorporeal 
liver perfusion. For this reason the present study was designed using autogenous 
extracorporealliver perfusion. 
Materials and Methods After making a porto-caval shunt in pigs (n=5), hepatectomy was 
performed, the liver preserved and the circulation restored with a cavo-caval shunt. Three 
hours after hepatectomy the liver was placed into the extracorporeal perfusion system 
cormecting the venous outflow of the left iliac vein with the left jugular vein. Haemodynamics 
of the pig were studied, and ex-vivo liver function was determined by 02-consumption, bile-
production (bilirubin in bile), clearance of bromo-sulfophtalleine (BSP) and NH3, and 
pathology. 
Results JVlacroscopically, the best achievable perfusion was realised with a pre- and 
posthepatic perfusion presure of 12-15 cm H20 and a flow-rate of 350 ml/min. However, 
microscopic examination of the liver demonstrated venous stasis mainly in the peripheral 
parts of the liver. Although a good function of the liver was established, an increasing lactate-
acidosis was measured, correlating with haemodynamic instability of the pig after 
approximately 3 hrs of ex vivo perfusion. 
Conclusions Although the liver in an extracorporeal circuit may give adequate hepatic 
support, this autogenous model demonstrates that irrespective of immunological responses, 
physiological parameters limit the period of effective use of extracorporeal liver perfusion. 
This finding has important consequences in the perspective of using xenogeneic livers for 
extracorporeal perfusion 
INTRODUCTION 
Extracorporeal liver perfusion has been used in the past to treat patients with acute liver 
failure 1.2. Although encouraging results have been obtained, this technique was abandoned in 
the early seventies, because of the successful development of the orthotopic liver 
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transplantation. However, mortality rates in liver disease remain high, because of the shortage 
of -in time- available donororgans. Patients with fulminant hepatic failure usually develop 
multiple organ disease, haemodynamic instability and hepatic encephalopathy. Because the 
liver has an enormous regenerative capacity after massive necrosis or partial hepatectomy, 
several alternative therapies are currently being investigated to gain time to either 
liverregeneration or a livertransplantation. Most of these techniques focus on the perfusion of 
the patients' blood or plasma outside the body through a device containing xenogeneic 
hepatocytes, since it 1S thought that the multiple and complex function of the liver can only be 
adequately replaced by metabolically active liver tissue itself. Although this technique shows 
promising results 3, it is a complex, time-consuming and expensive procedure. 
Extracorporeal liver perfusion (ECL) has been shown to stabilize the condition of patients 
with acute liver failure 4. At present transgenic pig livers are being used to study the 
immunological implications of extracorporeal liver support in the management of acute liver 
failure 5. However, it remains to be determined whether non-immunological aspects may limit 
the quality of extracorporeal liver perfusion. For this reason the present study was designed 
using an autogenous liver perfusion model. 
MATERIALS & METHODS 
Surgery. In pigs weighing 35-45 kg (n=5) anaesthesia was induced with an intramuscular 
injection of ketamine chloride (35mg/kg). The animal was intubated and ventilated, keeping 
the pig anaesthetized throughout the entire experiment. The end-expiratory CO2 was kept 
between 4 and 5%. Haemodynamic instability was only corrected using prewarmed NaCI 
0.9% or Haemacel; no whole blood or inotropica were used. Continuing haemodynamic 
monitoring was performed using a Schwann-Ganz catheter in addition to systemic 
measurement of central venous pressure and arterial blood pressure. Median laparotomy was 
petformed and the liver was freed by dissecting the triangular ligaments, the falciform 
ligament and all peritoneal attachments of the liver. The cystic duct and artery were ligated. A 
side-to-side portacaval shunt was made, followed by ligation and transection of the portal vein 
close to the hilum to create a functional end-to-side shunt. Then, the internal iliac vein and the 
internal jugular vein were cannulated using Gott-shunts (Shervvood, Davis & Geck, Veghel, 
the Netherlands), which were connected with a three-way connector (Baxter, Uden, the 
Netherlands) by heparin coated Tygon tubing (Baxter, Uden, the Netherlands) in order to 
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have a venovenous bypass (VVB); the third exit of the three-way connector was used for the 
perfusion system to the ex vivo liver. The VVB was filled, partially with the pigs' blood, 
partially with Nael 0.9% and freed of air. Hepatectomy was per.for.med. The isolated liver. 
was immediately perfused with ice-cold (O-4°C) UW-solution and put aside on ice for 
approximately 3,5 hours. The circulation in the pig was restored by a cavo-caval shunt using a 
GORE-TEX prothesis (Gore-tex, Flagstaff, Arizona, USA) of 12 mm diameter. A catheter 
was left in the portal vein in order to measure the portal blood pressure, after which the 
abdomen of the pig was closed. 
Table I o hr 2 hr 4 hr 6 hr 8 hr 10 hr 
HR (beats/min) 90 95 130 110 130 160 
BP (rrunHg) 110/80 120190 110/60 110/80 100/60 1l0nO 
CO (L/min) 4.1 6.2 4.3 3.5 4.6 5.4 
Wedge (nuuHg) 9 i 10 10 12 9 10 
CVP (nuuHg) 9 II 11 10 9 9 
Portal P (mmHg) 27 , 25 24 
Hb (mmo11L) 5.3 5.0 5.0 4.5 3.8 3.5 
Ht 0.30 0.29 0.31 0.25 0.21 0.19 
Thr ('lO'IL) 243 234 , 230 169 140 130 
Table I. TIle haemodynamic changes and haematological results every two hours throughout the 
experiment: 0-3 hours: surgery; 3-6 hours: anhepatic phase; 6-10 hours EeL (means of5 
experiments). 
Preparement oj the perfosion circuit. The perfusion circuit consisted of heparin coated Tygon 
tubing coming from the left internal iliac vein, through a roller pump entering the 
extracorporeal liver via the portal vein. A separate tube went directly from the carotid artery 
to the hepatic artery. The infrahepatic vena cava inferior was closed and the suprahepatic vena 
cava was cannulated using a Sump-drain (Sherwood, Davis & Geck, Veghel, the Netherlands) 
entering the anhepatic pig through the left internal jugular vein. Three-and-a-half hours after 
hepatectomy the liver was put in a sterile bag and put in a hot water bath set at 39°C, keeping 
the liver at a constant temperature of37.5°C. The hot water bath was put approximately 20 cm 
above the anhepatic pig. The anhepatic pig was 'treated' with the autologous ex vivo 
perfusion keeping a constant perfusion pressure of 12-15 em H20 and a constant flow-rate of 
375 mUmin. A time period of 4 hours was chosen because stable function was obtained within 
this time frame. 
Haemodynamics, ex vivo liver jimction and histology. Continuous monitoring of the 
haemodynamic parameters was performed and samples for biochemistry were taken every 
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half hour throughout the experiment and processed the conventional way. The function of the 
ex vivo liver was established in the following ways: systemic measurement of the clearance of 
bromosulphophtalleine (BSP)(Janssen, Geel, Belgium), which was administered (Smg/kg) 
four times, with the liver in situ, in the anhepatic phase and twice in the ECL-phase; systemic 
measurement of the clearance of NH3 throughout the experiment; oxygen consumption of the 
liver during perfusion was calculated substracting the oxygen-saturation in samples taken 
from the perfusion system directly pre- and postliver; bileproduction was monitored during 
perfusion and bilirubin in the bile was determined. Core needle biopsies were taken for 
histological examination. 
RESULTS 
Haemodynamics and haemaf%gy. Table I shows the haemodynamic changes and 
haematological data every two hours as measured throughout the experiment. Pigs were 
haemodynarnically stable throughout the surgical procedure and the anhepatic phase without 
the need of inotropica While blood pressure (BP), cardiac output (CO) and pulmonary wedge 
remained unchanged during the extracorporeal liver perfusion, there was significant increase 
in heart rate (HR) from the fourth hour on. The portal pressure was 24 mm H20, indicating 
Table II o hr 2 hr 4 hr 6 hr 8 hr , 10 hr 
Ureum (mmoliL) 4.2 4.0 3.6 3.1 2.2 2.7 
Creat (,.uuollL) 133 129 132 130 125 124 
Bili (l.uuoIIL) 2.4 3.3 5.7 4.6 5.0 4 
AF (ulL) 92 70 70 87 81 87 
ALAT (uIL) 39 30 27 23 ! 18 20 
ASAT (uIL) 26 I 48 86 74 103 230 
I yGt(uIL) 36 29 21 21 16 16 
LDH (uIL) 720 590 578 i 525 440 660 
Glucose (mmoIlL) 9 10.7 6.7 7.8 8.4 7.1 
pH 7.4 7.38 7.4 7.32 7.15 7.19 
Lactate (nunoUL) 2.3 i 2.7 2.9 2.0 6.3 9.6 
Table II. The biochemistry of the animal and the liver every two hours throughout the 
experiment: 0-3 hours: surgery; 3-6 hours: anhepatic phase; 6-10 hours EeL (means of 5 
experiments). 
67 
Chapter 4 
the existence of portal hypertension. No blood was lost in surgery, or during the anhepatic 
phase. There was a 30% decrease in the level of hemoglobin (Bb) and a 36% decrease in 
haematocrit (Ht) during the perfusion period, whereas the amount of thrombocytes (Thr) 
decreased until half the initial value during the 4th hour of perfusion. 
Biochemistry. The levels of ureum and creatinine did not change during the experiment 
accounting for a good renal function (Table II). Liver enzymes including AF, ALAT, yGt, 
and LDH remained unchanged throughout the experiment.. ASAT, however, increased 
gradually up to 10 times the initial level during the last two hours of perfusion. Systemic 
glucose and bilirubin concentration did not change significantly during the course of the 
experiment. Finally, during the ex vivo perfusion a decrease of 0.2 in the pH was observed, 
due to a metabolic acidosis; a 4-fold increase in lactate levels was observed. 
Function of the ex vivo liver. As can be seen in figure 1, oxygen consumption, measured by 
substracting the pre- and postperfusion saturation of the portal blood, was stable throughout 
the experiment. During a period of more than four hours oxygen consumption was 45% ± 4.8. 
In figure 2 bile production is shown during the 4 hours of perfusion, showing 4 m! of bile in 
the first hour and in the next three hours a mean production of 12 ml; no significant difference 
in production is found between the 2nd, 3rd and 4th hour. The amount of bilirubin in bile was 
2120 ± 466 )lg/ml in the first three hours of perfusion and 3895 ± 748 )lg/ml in the fourth 
hour accounting for functional liver metabolism. Clearance of BSP was measured 4 times 
(figure 3). The first time when the liver is in situ, with a normal t1/2 of 3.7 min; the second 
time during the anhepatic phase, in which BSP is cleared by excretion in urine (figures not 
shown) and t1/2 is 27.8 min; the third measurement was performed during the first hour of 
perfusion and the fourth during the last, demonstrating a tl!2 for BSP of 19.4 min and 18.9 
min respectively. 
The NH3-c1earance is shown in figure 4. NH3 was found to increase moderately in the first 
three hours of the experiment. From the beginning of the anhepatic phase on there is a 
significant increase of the concentration of Nlli, which is about 9 times as high as 
preoperative at the highest point. The Nrh concentration returns to about 5 times the original 
level in 4 hours of ex vivo liver perfusion. 
Histopathology of the liver. Macroscopically, optimal perfusion of the ex vivo liver was 
obtained with a constant flowrate of375 mllmin and a perfusion pressure of 12-15 em H20. 
The central parts of the liver remained unchanged throughout the experiment: normal light 
brown liver tissue. However, towards the end of the experiment, the peripheral parts of the 
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liver showed a color change from light brown into purple and a loss of softness. On 
histopathological examination, normal liver tissue was shown in the central part of the liver, 
although a slight neutrophil invasion and some steatosis could be noticed. (figure Sa). The 
peripheral part, on the other hand, clearly showed stasis of blood: enlarged sinusoids filled 
with erythrocytes (figure Sb), therewith confirming our findings during perfusion. 
DISCUSSION 
In the past three decades, a number of studies using extracorporeal liver perfusion for the 
treatment of patients with acute liver failure have been performed; the results were promising 
as to temporary enhancement of the patients' neurological condition, although no 
improvement in survival was obtained 1.2. Most of these studies were done before large scale 
introduction of orthotopic liver transplantation. At present, liver transplantation is very 
successful with survival rates of 70-80%. However, because of the shortage of available 
donororgans in the United States, only 20% of the patients with liver failure receive a liver 
transplantation, whereas 80% dies while being on the waiting list 5. Therefore, there is a 
clinical need for a temporary liver function replacement, which renewed the interest in the 
extracorporealliver perfusion 4.7. 
After initial experiments in animals, most experience has been obtained from clinical studies, 
in which very sick patients with hepatic failure are usually managed in the leU. In order to be 
able to asses the haemodynamic and metabolic changes and the actual liver function during 
the use of an ex vivo liver perfusion system, we studied these parameters in an anhepatic pig 
model, in which no major correction of haemodynamic or metabolic parameters occured. 
As has been shown, pigs remain haemodynamically stable during more than S hours after 
hepatectomy and survival of anhepatic pigs is at least 24 hours 8. In the experiments 
performed in our laboratory, no haemodynamic instability was observed during surgery or in 
the anhepatic phase. However, more than three hours of extracorporeal liver perfusion 
resulted in gradually progressive haemodynamic and metabolic changes. Part of this 
haemodynamic instability may be due to dilution of blood as can be concluded from the 
decrease in hemoglobin and haematocrit, and part of it may be due to the changed physiology 
of the abdomen in our model inducing portal hypertension. Most experiments did end with a 
positive fluid balance, with a considerable amount of ascitic fluid in the abdomen as well as in 
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the liver perfusion bag. As has been demonstrated before, the ascitic fluid from the ex vivo 
liver should either be collected into a reservoir and returned to the patient after mixing with 
the patients blood 1, or discarded and replaced by reconstituted human plasma 9. 
Although haemodynamic changes were noticed, good function of the liver was measured 
during the four hours of ex vivo perfusion as determined by oxygen consumption and 
clearance ofBSP and NH3. Bile production was 4 ml in the first hour and increased to a fairly 
constant production of 12 ml in the next three hours. This indicates, that the liver is 
immediately capable of metabolic processes requiring oxygen such as detoxification, but the 
conjugation of bilirubin and the production of bile takes more time, which is comparable with 
literature and our experience with biieproduction in orthotopic livers transplanted into 
humans. Although the level of NH3 decreased most in the first hour, based on our experience 
at least several hours of perfusion are necessary for optimal treatment with ex vivo liver 
perfusion, despite the haemodynamic instability that occured in the last hour of perfusion. 
On macroscopic and microscopic examination of the ex vivo liver, hypoperfusion of the 
peripheral parts of the liver were observed. Acidosis may have been the consequence of 
organic acid accumulation, e.g. as a result of hypoperfusion of the gut due to portal 
hypertension, or due to ex vivo hepatic hypo perfusion of the peripheral liver. At the end of the 
experiments, a lO-fold increase in ASAT was measured, the liver enzyme known to be the 
most sensitive indicator for liver cell damage. In our study we were not able to determine the 
cause of the metabolic acidosis, although improved ex vivo liver perfusion could diminish the 
metabolic problems encountered in ex vivo liver perfusion. Improved perfusion of the liver 
may be obtained when the liver is put on a diaphragm in a perfusion chamber ventilated with 
IPPV, thereby mimicking the physiological conditions of the liver ]0. 
Bertrand et al claimed from their study performing 15 short term perfusions on 10 patients the 
same outcome for perfusions less than one and a half hour as compared to more than two and 
a half hours II Whether patients with acute liver failure would benefit most from long term 
perfusion with one liver or multiple short term liver perfusions remains to be determined. It 
should also be noticed that biochemical improvement as measured in our experiments, does 
not necessarily correlate with neurological improvement 1.9. In a clinical situation hepatic 
encephalopathy with increased cranial pressure is one of the major causes of death. Moreover, 
bleeding disorders causing major complications in patients with acute liver failure might not 
be prevented or may even be enhanced in extracorporeal liver perfusion, because of the 
damage done to platelets in the extracorporeal perfusion system. 
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A 
B 
Figure 5a. HE-staining of a liver biopsy of the central part of the liver showing only slight 
neutrophil invasion in zone one and normal liver tissue towards the central vein (to the right). 
Figure 5b. HE-staining of a liver biopsy taken of the peripheral part of the liver evidently 
showing stasis of blood, enlarged sinusoids filled with erythrocytes towards the central vein. 
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Our experience indicates that extracorporeai liver perfusion is technically feasible and 
provides a rather simple and rational method of temporary hepatic support with an excellent 
function of the ex vivo liver. In our model we demonstrated the occurrence of metabolic 
acidosis, which should be taken into account when further development of this technique is 
considered, since this may limit the quality of extracorporeal liver perfusion. Future studies 
should adress the immunological implications of this method in a xenogeneic model, possibly 
with the use of transgenic animals, before it can be applied safely in patients with acute liver 
failure. 
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Acute liver failure attenuates hyperacute xenograft rejection 
Stockmann HBAC, Hiemstra CA, Meijer R, Marquet RL, IJzermans JNM. 
Adapted form Transplantation Proceedings 2000; 32: 1114-1115. 
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ABSTRACT 
Pig livers, transgenic for complement regulatory proteins (CRP), are being used to study the 
feasibility of extracorporeal liver support in the management of acute liver failure. However, 
thus far, effective temporary ex vivo liver perfusion has been applied without immunological 
drawbacks. Complement is known to play a major role in hyperacute rejection in 
xenotransplantation and the level of complement is significantly decreased in patients with 
acute liver failure. We examined the possibility of prevention of the hyperacute rejection in a 
guinea pig heart to rat transplantation model. 
Acute liver failure was induced in rats using Galactosamine (300-1000mg/kg). After 24 hours, 
a guinea pig heart was transplanted into the rat and survival of the transplanted heart was 
observed. C3, CHso and biochemistry of the liver were measured at 1,6,24 and 48 hours and 
deposition of complement in the transplanted heart was established. Animals treated with 
CVF (Cobra Venom Factor) and a group receiving no treatment were taken as controls. 
All GALAC-treated animals showed severely disturbed liver function at the moment of 
transplantation. C3 and CHso levels at 24 hours were 50% decreased. Non-treated controls 
rejected in 14 to 36 min (median 22 min.). Hearts in CVF-treated animals were rejected after 
1 day. There was no difference between animals that had received either 600 or 1000 mglkg 
GALAC. Most animals of this group did not survive the transplantation procedure and died 
on the operating table with a functioning transplant (median survival time> 45 min.). 
Animals given 300 mg/kg GALAC sustained the operation well and rejected their transplants 
after 26 to 270 min. (median 57 min.). Immunohistochemical staining for Cig and C9 was 
positive in all specimens but revealed no differences between hearts from nontreated controls 
and grafts from GALAC-treated animals. 
These experiments show an increase in xenograft survival time in rats with acute liver failure, 
probably due to a significant decrease in complement levels and activity as can be measured 
in rats with CVF-induced complement depletion. Therefore, transgenesis for CRP may not be 
necessary for successful temporary xenogeneic perfusion in the treatment of acute liver 
failure. 
INTRODUCTION 
The lack of immediate availability of a donor liver implies that many patients with acute liver 
failure die before a liver transplantation can be performed. Extracorporeai pig liver perfusion 
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is one of the options for temporary liver support. The concept stems from the 1960s, but the 
improved success rate of liver transplantation for acute hepatic failure and progress in 
xenogeneic immunobiology has rekindled interest in this technique I. It is known that patients 
with acute liver failure become immunosuppressed, which is thought to be partly due to a 
defective synthesis and increased consumption of complement 2. This potentially life-
threatening complication may be beneficial if extracorporeal pig liver perfusion is considered; 
it may prevent the occurrence of hyperacute rejection (HAR). And indeed, in most clinical 
trials on extracorporeal liver perfusion utilizing normal pigs, classical HAR is not seen 3. This 
could mean that the use of livers from pigs that are transgenic for human complement 
regulatory proteins is not essential to enable uncompromised short-term liver perfusion. The 
aim of the present study was to investigate whether acute liver failure might provide a 
window of opportunity for the acceptance of a discordant xenograft. 
MATERIALS AND METHODS 
The experiments were performed using male Wistar rats (Harlan CPB, Austerlitz, the 
Netherlands) weighing 200-250 g and female Dunkin Hartley guinea pigs (Harlan CPB, 
Austerlitz, the Netherlands) weighing 200-250 g. They were kept under controlled laboratory 
conditions and received food and tap water ad libitum. When treatment had started, the rats 
had free access to 10% glucose water. The experiments were approved by the Committee of 
Animal Research of the Erasmus University. D-Galactosamine (Sigma) was dissolved in 
phosphate buffered saline (PBS, Sigma P-44l7), pH 7.4 at desired concentration. The animals 
were divided into three groups. In group 1, acute liver failure was induced by injecting 300 
(n~6), 600 (n~3), or 1000mglkg (n~8) galactosamine (GALAC) intraperitoneally. Blood 
samples were obtained by orbital punction at 1,6,24, and 48 hours after injection. Levels of 
CH50, C3, NH3, ALAI, ASAT, AF, Bili, Urea and Creatinine were measured. After 24 hours a 
guinea pig heart was transplanted heterotopically as described elsewhere 4, and the duration of 
the heart beating was assessed by abdominal palpation. Group 2 (n~6) received no GALAC, 
but was treated 1 day before guinea pig heart transplantation with a single dose i. p. of 9000 
units of cobra venom factor (CVF). Group 3 (n=5) did not receive any treatment before 
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Figure 2. Concentration of AF 
and bilifilbin (mean ± sd) 
xenotransplantation. \Vell-functioning hearts from the 300 and 600 mg/kg GALAC groups 
beating for longer than 30 min. and from the nontreated control group beating for about 10 
min, were used for immunohistochemical analysis. Complement factors CIq and C9 were 
stained by rabbit anti-rat antibodies and secondary FITC-Iabelled swine anti-rabbit antibodies 
(Dako ITK Denmark) and analyzed by fluorescence microscopy. 
RESULTS 
In figure 1 the concentrations of the liver enzymes ALAr and ASAT are shown. There is a 
significant increase correlated to the concentration of GALAC used in all groups in the first 
24 hours accounting for severe liver cell damage. At 48 hours, the levels of ASAT and ALAT 
decrease 10 one third of the level a1 24 hours in the animals treated with 300 and 600 mg/kg 
GALAC, whereas in the animals treated with 1000 mg/kg GALAC the enzymes continue to 
increase to double the amount at 24 hours. Figure 2 shows the results for AF and bilirubin. In 
all groups there is a decreases of AF at 6 hours, an increase above the intitial value at 24 hours 
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and a decrease again at 48 hours. There is no significant difference amongst the groups or 
between the different time points in the concentration of AF. In the first 24 hours, bilirubin 
shows a steady increase to 75 ± 35 ).lg/mL in the GALAC-300 group, 24 ± 8 ).lg/mL in the 
GALAC-600 group and 19 ± 5 ).lg/mL in the GALAC-IOOO group. At 48 hours, the level of 
bilirubin continues to rise for GALAC-300 to 19 ± 15 ).lg/mL, GALAC-600 to 51 ± 27 ).lg/mL 
and GALAC-l 000 to 156 ± 41 flg/mL. The concentration of NH3 is shown in figure 3. In all 
three groups, there is a steady increase to 380 ± 40 J.lglmL at 48 hours. No difference amongst 
the groups is detected. Figure 4 shows the kidney-function in all groups represented by urea 
and creatinine concentration. There is no major decrease in kidney function during the 
experiment. 
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Figure 3. Concentration ofNH3 (mean ± sd) 
The amount of total complement (CHso) in the animals treated with 300 mg/kg GALAC and 
the amount of complement factor 3 (C3) in all three groups is shown in figure 5. There is a 
significant decrease ofCHso in the GALAC-300 group at 24 hours showing again an increase 
at 48 hours. In the animals treated with 600- 1000 mg/kg GALAC, the level of complement 
factor 3 decreases from 0.44 ± 0.07 gIL to 0.21 ± 0.01 gIL at 24 hours and then increases to 
0.25 ± 0.05 gIL at 48 hours. In the animals treated with 300 mg/kg GALAC, the concentration 
of complement factor 3 decreases from 0.60 ± 0.03 gIL to 0.32 ± 0.07 gIL, and remains 
constant in the second 24 hours (0.30 ± 0.06 gIL at 48 hours). 
Table 1 shows the actual survival times of the transplanted guinea pig hearts to rats with acute 
liver failure, treated with CVF or receiving no treatment at all. When no treatment was given 
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Figure 5. Concentration of C3 
and CHso (mean ± sd). 
the survival times varied from 14 to 36 min (median 22 min.). With an injection of9000 units 
of Cobra Venom Factor (CVF) 24 hours before transplantation, the survival of the graft was at 
least one day. There was no difference in survival of the heart graft between animals that had 
Table 1. Survival of Guinea Pig hearts grafted in rats with acute liver failure 
Treatment 
None 
CVF 
GALAC 600-1000 mg/kg 
GALAC 300 mg/kg 
Survival time (min.) 
14-15-15-32-36 
1-1-1-1-1-1 
16* - 30-33 -35* - 37 -45* 
47* - 51 * -60* - 67* - 80' 
26 - 30 - 52 - 63 - 120 - 270 
Liver failure was induced by a single injection of galactosamine (GALAC) 24 hours before 
heart transplantation. CVF: 9000 units on day-I. 
'Animals died with functioning graft. Groups 3 and 4 vs I: p< 0.05. 
received either 600 or 1000 mg/kg GALAC, therefore they are presented as one group. Most 
animals died with a functioning transplant on the operating table due to acute liver failure 
with subsequent anaesthesia and surgical procedure. Mostly coagulation problems were 
encountered. The median survival time of the graft, however, was 45 min. (range 16-80 min.), 
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which was significantly longer than in the non-treated group. The animals treated with 300 
mg/kg GALAC did survive the procedure and significant longer survival times were found 
(median survival time 57 min, range 26 to 270 min.). 
The deposition of C I q and C9 on liver tissue sampled from well-functioning grafts for longer 
than 30 min. from the 300 and 600 mg GALAC groups and from the non-treated control 
group beating for 10 min. was established. The results for complement factor 9 are shown in 
figure 6. Although on first sight there seems to be more neutrophil invasion in the control 
group as compared to the GALAC-treated group, no difference in C9-deposition can be 
established between the two bTfOUPS. 
DISCUSSION 
Patients with hepatic disease have an impaired antibacterial host defense possibly due to 
impaired hepatic synthetic function 2.5. Knowing that the liver is the major site of production 
for the complement proteins C3, C6, Cs, and factor 12 6, a severely compromised complement 
activity can be seen in these patients, which appears to be multifactorial in origin and involves 
all aspects of the complement system including the classical activation pathway, the 
alternative activation pathway, the terminal cascade, and critical regulatory proteins 7. It is 
unclear, however, whether the complement deficiency is the result of the impaired synthesis 
of components alone, an ongoing activation of the complement system, or a combination of 
the two. Because of this deficient complement activity, systemic bacterial infection is one of 
the major complications in patients with chronic hepatic disease. 
On the other hand, patients treated for acute liver failure could possibly benefit from this 
compromised condition. It is known that the complement system plays a major role in 
hyperacute rejection, e.g. complete inactivation of complement can fully prevent hyperacute 
rejection s. Also in our study, we demonstrated the absence of hyperacute rejection when the 
animals were treated with Cobra Venom Factor (CVF), which resulted in a one-day survival 
of the xenogeneic heart transplant, whereas in the untreated group hyperacute rejection was 
shown. Therefore, the compromised activity of the complement system may possibly explain 
the fact that thus far, classical HAR is not seen in most clinical trials on the treatment of 
patients suffering from acute liver failure with extracorporealliver perfusion utilizing normal 
. 3 pigs. 
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Figure 6. immunohistochemical staining with rabbit anti-rat C9 antibodies of well-functioning hearts 
from the non-treated control group beating for 10 min (fig. 6a) and the GALAC-600 group beating for 
30 min (fig. 6b). The hearts from the control group show evident ly more tissue damage, but no 
significant difference in the intensity of staining could be established between the two groups. 
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And indeed, in our animal model, all GALAC-treated animals showed severely disturbed liver 
function at the moment of transplantation and C3 and CHso levels were 50% decreased, which 
led to an increased survival of the xenograft. To some extent this may be due to observed 
reduced circulating levels of complement, although this was not substantiated by a reduced 
deposition of complement in nonrejecting grafts. On the other hand, it is likely that other 
factors, such as a diminished coagulability as observed during surgery and impaired antibody 
production also contributed to the attenuation of hyperacute rejection. 
Our results suggest that the severity of liver failure and the subsequent amount of circulating 
complement is correlated to the extend of xenograft survival. In most clinical studies only 
patients with severe acute liver failure were treated with extracorporeal perfusion 9, possibly 
providing the least harmful xenogeneic circumstances, for which reason no hyperacute 
rejection was seen in these patients. Furthermore, although the increase in survival time 
induced by liver failure was only small, it can be argued that it might have been larger if a 
xenogeneic liver had been transplanted. It has been demonstrated frequently that the liver is 
less susceptible to the harmful effects of antibody and complement than other organs 10. 
In conclusion, these results indicate that acute liver failure induced by galactosamine 
facilitates the acceptance of a discordant xenograft. The decreased susceptibility of the liver 
added to our current observation that recipients with acute liver failure are less prone to 
hyperacute rejection, suggests that short-term extracorporeal perfusion using non-transgenic 
xenogeneic pig livers is a relatively safe procedure. 
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ABSTRACT 
We reported previously that no classical features of hyperacute rejection CHAR) could be 
found in liver grafts in the guinea-pig (GP)-to-rat model and that recipients died shortly after 
transplantation, because of non-immunological causes. Thus, the GP-to-rat model is not 
suitable for studying the mechanisms of discordant liver xenograft rejection. In the hamster to 
rat model, long-term survival of a liver graft is possible, but extremely low levels of 
xenoreactive natural antibodies are present. To mimic a discordant situation with preformed 
IgM and IgG antibodies, we sensitised rats one or five weeks before grafting. Specific anti-
hamster IgM antibodies were found in recipients sensitised at week -1, but not week -5. Anti-
hamster IgG was present in all recipients, albeit considerably higher in animals sensitised five 
weeks before grafting. In these two models, we examined the mechanism of HAR of liver 
grafts and compared this with heart xenografts. Control heart and liver grafts rejected in 4 and 
7 days after transplantation respectively. Liver grafts in recipients sensitised at week -5 showed 
venous congestion and bleeding after reperfusion, indicating HAR, however this was not 
observed following sensitisation at week -1. This surprising finding was confirmed by 
histology. Massive extravasation, edema, and acute liver cell degradation were noticed in grafts 
subjected to HAR. Liver grafts of recipients sensitised at week -1 showed only minimal 
changes. Heart grafts were rejected hyperacutely in both sensitisation models. IgG antibodies 
could be detected on liver grafts in the group sensitised at week -5 but not in the 
group sensitised at week -1. ::vfinimal IgM depositions were found on liver grafts of animals 
sensitised one week before grafting. Rejected heart grafts of similar sensitisation groups 
showed identical antibody depositions; only IgM depositions were massive. Complement 
depositions were found in all groups. These results indicate that IgG, but not IgM, mediates 
HAR in hepatic xenografting. Such a predominance of IgG over IgM does not exist for heart 
grafts. 
INTRODUCTlOl\ 
Transplantation of transgenic organs or tissue between widely disparate species as the ultimate 
solution for donor shortage shows promising results 1. However, many aspects of rejection are 
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still unknown. as evidenced by the muddle of immunosuppressive drugs that are needed to 
keep pig organs functionaL Using small animals, the guinea-pig (GP)-to-rat rodent model 
provides an easy and fast way to study the basics of discordant transplantation. The recipient 
produces preformed xenoreactive natural antibodies (XNAs) against the GP, which are capable 
of rejecting heart grafts in a hyperacute manner 2. XNAs are mainly IgJ\II type 3, but some 
donor-specific IgG antibodies have been detected 4. 
For allogeneic grafting, the relative insensitivity of liver grafts to antibody-mediated rejection 
has been described 5.6. In a previous publication, we investigated whether this phenomenon also 
occurred in the GP-to-rat liver transplantation model 7. We demonstrated that a 'rejected' GP 
liver was not characterised by the classical features of hyperacute rejection (HAR) 7. However, 
recipients died within a few days, apparently because of non-immunological reasons. 
Therefore, no firm conclusions could be drawn regarding susceptibility of discordant liver graft 
toward antibody-mediated rejection 7. Numerous studies have reported long-term survival of 
hamster grafts, indicating no interference of non-immunological problems in this model 8-10. 
However, the rat has very low titres of preformed antibodies to hamster. To mimic a 
discordant situation with preformed IgM or IgG antibodies, we sensitised recipients with donor 
blood at one or five weeks before transplantation. 
Hence, the aim of the current study was to analyse the mechanism of HAR of liver xenografts 
in the presence of preformed antibodies and to compare this with the rejection of heart 
xenografts. 
MATERIALS AND METHODS 
Animals. Female Syrian hamsters were used as donors and male Brown Norway rats as 
recipients. All animals were obtained from Harlan c.P.B. (Austerlitz, The Netherlands). They 
were kept under controlled laboratory conditions and received food and tap water ad libitum. 
Hamsters weighing over 120 grams and rats weighing between 250 and 300 grams were used. 
The experimental protocols adhered to the rules laid down in the "Dutch Animal 
Experimentation Act" (J 977) and the published "Guidelines on the Protection of Experimental 
Animals" by the Council of the EC (1986). The specific protocol was approved by the 
"Committee on Animal Research" of the Erasmus University Rotterdam, The Netherlands. 
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Liver transplanfalion. Orthotopic liver transplantation (OLT) was performed according to a 
previously described method with some donor-related modifications 7,1l. The modifications 
were (1) donor pre-treatment with 0.1 mg/kg atropine (Centrafarm Services, Etten-Leur, The 
Netherlands), and (2) the outside diameters of the Teflon cuffs were 2.1 mm and 1.79 rnm for 
the lye and PV, respectively. Recipient death was taken as the endpoint of rejection. 
Heart transplantation. Heterotopic abdominal heart transplantation (HTx) was perfonned as 
described by Ono and Lindsey 12. Cessation of heartbeat as evidenced by abdominal palpation 
was taken as the endpoint of rejection. 
Sensitisation. Hamster blood was obtained by orbital punction. One milliliter of heparinised 
blood was injected Lv. into the penile vein of the recipient one or five weeks before organ 
grafting. 
Haemaggilltinalion assay. Total antibody and IgG levels were measured using a 
haemagglutination assay. Plasma samples, taken immediately before grafting, were serially 
diluted. A suspension of freshly prepared hamster erythrocytes (4%) was added in equal 
amounts. After 1 h of incubation at 37°C, the wells were screened for agglutination. The 
dilution at which agglutination still occurred was considered the haemagglutination titre. For 
IgG level measurements, plasma samples were treated with 0.5 rnl'v1 dithiotreitol for half an 
hour at 37°C to deplete IgNl. Normal BN-serum was taken as negative control. Estimations of 
IgM titres were calculated by subtracting IgG titres from total antibody titres. 
Histology and immunohistochemistry. After rejection of the grafts, necropsy was performed. 
The heart graft or upper liver lobe was removed and processed for histology and 
immunohistochemistry. Paraffin sections were stained with haematoxylin-eosine and examined 
with conventional light microscopy. The slides were examined for extravasation, edema, vessel 
damage, and infiltration. Changes were noted as compared to naive grafts and scored from -
(no changes) to +++ (sevele changes). 
For antibody, complement depositions and natural killer (NK) cell infiltration, 
immunohistochemistry on frozen sections was performed. Macrophages were identified on 
paraffin sections. FITe-labelled mouse anti-rat antibodies to demonstrate IgM, IgGl, IgG2a 
and IgG2b were used (1: I 0; PharMingen, San Diego C~ USA). IgG2c and complement C3 
were demonstrated by FlTC-conjugated rabbit anti-sheep (1:100; DAKO AlS, Glostrup, 
Denmark) to sheep anti-rat antibodies (1 :500; ANAWA Trading N~ Wangen Zurich, 
Switzerland). Complement factors Clq and C9 were stained by rabbit anti-rat IgG (1:25, 
1600, respectively, kindly provided by Dr. B.P. Morgan) and secondary FlTC-labelled swine 
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anti-rabbit (DAKO AlS). Rat spleen was taken as positive control, whereas liver and heali 
from naive hamsters were used as negative controls, The slides were analysed by fluorescence 
microscopy. Location of the depositions was noted and the fluorescence intensity was scored 
from - (no depositions) to +++ (massive depositions). A 3-step indirect Ni-DAB 
immunoperoxidase staining was performed on paraffin slides to demonstrate macrophage 
infiltration. \;Jouse anti-rat macrophage was lIsed as primary antibody (ED 1, 1 :800; Serotec 
Ltd., Oxford, UK). Staining was performed with Ni-DAB substrate after the application of 
rabbit anti-mouse PO and swine anti-rabbit PO antibodies (1 :250; DAKO NS). Applying the 
same protocol, NK cells were demonstrated on frozen sections using mouse anti-rat NK cells 
(NKR-PI, 1 :400; Endogen, Woburn MA, USA). Conventional light microscopy was used to 
analyse the infiltration. 
Exper;mental design. Heart and liver transplantations were carried out in different recipients. 
Sensitisation with 1 ml of hamster blood was performed 1 week before transplantation 
(l-week sensitized) in groups 2 and 5, and 5 weeks before transplantation (5-week sensitized), 
for groups 3 and 6. Groups 2 and 3 received heart grafts (n=5 for both); groups 5 and 6 
obtained liver grafts (n=7 and n=5, respectively). Non-sensitized control groups were included 
for both heart (group 1, n~7) and liver transplantations (group 4, n~8). On day 0 the recipients 
obtained a heterotopic heart graft or orthotopic liver graft. Survival, as determined by 
abdominal palpation or death, was scored in minutes, hours or days, depending on the 
treatment. At necropsy the heart graft or upper liver lobe was removed and processed for 
histology and immunohistochemistry. Heart and liver grafts were semi quantitatively scored for 
type and quantity of antibody and histological changes. 
Statistics. Statistical evaluation of the survival data was carried out for both heart and liver 
grafts. In cases of differences in variances as tested by Levene's test, mathematical 
transformation of the survival data was carried out. This was done to reduce the influence of 
outlying values. "One-way" analysis of variance (ANOVA) was performed on these data. If the 
ANOVA was significant on a 5% level, the Duncan's multiple comparison test or Games-
Howeli test was carried out for possible differences among the means. The tests were 
corrected for the fact that the comparisons were not statistically independent and for unequal 
group sizes. 
Probability values lower than 0.05 were considered statistically significant. Survival of 
transplants with clear evidence of no rejection (liver enzymes, histology) was discarded from 
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statistical evaluation. All computing was done using the statistical software package SPSS for 
Windows, release 7.5.2. 
RESULTS 
Histology. Specimens of the transplanted organs were obtained for histological examination 
after killing the animals at the moment of rejection or death. Heart grafts rejected by noo-
sensitised rats showed vessel destruction, extravasation, edema and polymorphonuclear cell 
infiltrate, suggesting an antibody-mediated rejection. Also presence of mononuclear cells was 
noted. Groups 2 and 3 showed more severe extravasation of erythrocytes, fibrosis and edema. 
The overall architecture, including most vessels, was intact. In some cases, polymorphonuclear 
granulocytes were found. 
Control liver grafts demonstrated polymorphonuclear infiltrate, destroyed vascular morphology 
with destroyed endothelial cell layers, edema, and a more predominant mononuclear cell 
infiltrate than heart grafts, consisting of lymphocytes, lymphoblasts, monocytes and 
macrophages_ This indicates a mixture of cellular as well as antibody-mediated rejection. The 
infiltrate was situated around the portal areas. 
Table l. Histological changes in heart and liver grafts, rejected by sensitised recipients. 
Group Treatment Extravasation Oedema Vesse~ Infiltration 
damage 
HTx, non-sens + ++ ++ +++ 
2 HTx, l-wk sens ++ ++ + ± 
3 HTx, 5-wk sens ++ ++ + ± 
4 OLT, non-sens + ++ ++ +++ 
5 OLT, J-wk sens + + + ± 
6 OLT, 5 wk-sens +++ + +++ + 
Scores varied from - (no changes) to +,..;... (severe changes) compared to naive heart/liver. 
Liver grafts of l-week sensitized recipients showed extravasation, edema, signs of fibrosis, and 
vascular congestion, but little vessel damage. Focally, mononuclear granulocytes were found. 
Specimens of liver grafts in group 6 revealed extensive tissue damage, extravasation and acute 
liver cell damage. Semiquantitative histology scores are listed in Table 1. 
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Immunohistochemisi7y, Frozen sections of heart and liver grafts were stained for IgM, IgG 
subtypes, complement CIg, C3 and C9, and ~1(-cell infiltrates. Paraffin sections were used to 
stain for macrophages. All control stainings were positive on untreated rat spleen, whereas 
untreated hamster liver and heart sections were negative. 
Control hearts showed major IgM depositions. Some IgG2a type antibodies and macrophages 
were noticed. Liver grafts from untreated rat recipients showed minor antibody depositions on 
cellular infiltrates or portal field, mainly being IgM. Macrophages, but not NK cells were 
deposited throughout the tissue 
Heart grafts from l-week sensitized recipients demonstrated massive antibody depositions, 
whereas liver grafts demonstrated minor depositions. In group 3 and 6, moderate IgG 1 
depositions could be demonstrated. Additionally, depositions of IgG2a and IgG2b were 
detected on myocytes. For liver grafts depositions of IgG2b were found. Semi-quantitative 
antibody deposition scores are listed in Table 2. 
Table 2. 
Groups 
1 
2 
3 
4 
5 
6 
Antibody depositions in rejected heart and liver grafts by sensitised recipients. 
Treatment IgM IgGl IgG2a IgG2b IgG2c 
HTx, non-sens +++ + 
HTx, l-wk sens 
HTx, 5-wk sens 
OLT, non-sens 
OL T l-wk sens 
OLT, 5-wk sens 
+++ 
~ 
± 
++ + 
± ± 
..l..-;-' ± 
+ 
± ± 
+ 
Scores varied from - (no depositions) to +++ (massive depositions). 
Liver grafts from untreated rat recipients showed some C1g depositions, but no C3 and C9, 
whereas an measured complement components could be detected on heart grafts. Sensitising 
rats one week before transplantation resulted in moderate C3 depositions in both heart and 
liver grafts. In addition, positive Kupffer-cells were found. CIg could only be detected in heart 
grafts, whereas little C9 was found in liver grafts. In 5-week sensitized recipients, massive C3 
and moderate C9 depositions were demonstrated for heart grafts. Moderate C3 depositions 
and to a lesser extend CIg could be shown for liver grafts in group 6. 
Graft survival. Heart and liver grafts showed a homogeneous reperfusion after releasing the 
clamps. After a few minutes, the heart grafts turned dark red. Liver grafts in group 6, but not 
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group 5, were purple and showed swelling 2 minutes after reperfusion. !vtost of the recipients 
of liver grafts died showing the clinical signs of shock. 
Graft survival times are shown in Table 3. A highly significant difference was demonstrated 
between the group means in the heart transplanted groups (p=O.OOO, srcs=35.730) and between 
the group means in the liver transplanted groups (p=O.OOO, sre,=O.567). Non-sensitised heart 
graft recipients showed prolonged survival compared to both other heart graft recipients 
(p<O.OOl, both). No difference was found between I-week sensitized and 5-week sensitized 
animals. The survival times of the non-sensitized group receiving liver grafts were significantly 
longer compared to groups 5 and 6 (p=O.OOO, both). Survival times of groups 5 and 6 were not 
significantly different, but a trend was noticed (p=O.081). 
Table 3. Survival times following 'pseudo-discordant' heart and liver transplantation. a 
Grou,e Sur~e!l Treatment Survival times Median survival 
1 HTx non-sens 3,4,4,4,4,4,4 days 4 days 
2 HYx l-wk sens 5,6,7, 120, 165 minutes 7 min. 
3 HYx 5-wk sens 3, 3, 3, 9, 1O minutes 3 min. 
4 OLT non-sens (3), (4), 6, 6, 7, 7, 8, 8 days 7 days 
5 OLT l-wk sens IV:!, IVz, 2, 2V:!, 3, 21, 25 hours 2Vz hours 
6 OLT 5-wk sens 1, 1, IV4, 1114, 11/2 hours 1 Y4 hours 
aHamster heart or liver was grafted in BN rat after sensitisation to hamster-blood at 1 week 
(group 2 and 5) or 5 weeks (group 3 and 6) before transplantation. In control groups 1 and 4, 
hamster heart or liver was grafted into naive BN rat. Both control groups were statistically 
different from their sensitisation groups. Survival times of animals that died with a functioning 
graft are put between parenthesis. 
JgM and JgG agglutination litres. Haemagglutination tests revealed the presence of specific 
anti-hamster IgM antibodies in I-week sensitized animals on day O. The IgM titre was 
negligible in recipients sensitised 5 weeks before grafting. Anti-hamster IgG was present in all 
recipients, albeit considerably higher in recipients sensitised at week -5. Nonnal BN-serum 
revealed agglutinating titres of one-quarter or lower. No statistically significant correlation was 
found between pre-operative antibody titre and survival or histological changes in either 
sensitisation group. 
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DISCUSSION 
The immuno-privileged position of liver grafts to antibody-mediated rejection has been a 
research subject for many years. Prefonned antibodies in the circulation of patients before 
transplantation have been identified as the cause ofHAR of allografts 13. However, hyperacute 
antibody-mediated rejection is not necessarily observed 5,14. Liver allografts seem to be less 
susceptible to antibody-mediated rejection. The phenomenon of reduced susceptibility has been 
demonstrated in previous studies concerning experimental liver allotransplantation in 
(sensitized) recipients 6.15. In discordant liver grafting, we and others were unable to resolve 
this question, because the recipients died from non-immunological problems 7.16. For that 
reason, we performed the current experiments. Similarly, as described by others, we found that 
non-sensitized controls rejected hearts significantly earlier than liver grafts 10,17. Histologically, 
control heart grafts showed a prominent vascular rejection process, whereas rejected liver 
grafts (group 4) revealed a more predominant cellular rejection with mononuclear cell 
infiltrates. Moreover, antibody depositions of the Igl\.1 type were more pronounced on heart 
grafts than liver grafts. These findings indicate that in the untreated concordant hamster to rat 
combination the liver might be less affected by IgM. 
It can be argued that liver grafts are less immunogenic compared to heart grafts, resulting in a 
diminished and sluggish antibody response resulting in less damage. However, this is not very 
plausible, because anti-donor antibody levels peak around day 5-7 for both liver and heart 
transplantation 18-20. Moreover, Murase et al 21 reported that cytotoxic antibody titres after 
xenogeneic liver grafting are 10 times higher than after heart grafting. Infusion of hamster 
hep"tocytes or non-parenchymal liver cells was able to induce high cytotoxic antibody titre 
within 1 week and. splenic response to liver grafts is even higher then to cardiac grafts 22,23. 
This indicates that liver grafts may be at least as immunogenic as heart grafts. 
Another plausible explanation is that the liver graft protects itself, because the source of 
complement and the target organ are the same, leading to prolonged survival 24. This is in 
accordance with the time required to transform the proteins to donor type profile 7,25. 
Nevertheless, residual recipient complement components and neo-synthesis, by macrophages, 
monocytes, and fibroblasts, are still able to cause lysis 24. 
In normal BN-serum, haemagglutinating antibodies were almost non-detectable. In the 
discordant situation, grafted organs encounter high titres of preformed antibodies. 
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Immunogenicity is, therefore, of less relevance than the affinity of antibodies for the different 
tissues. To mimic the preformed antibody situation, we sensitized rat recipients with hamster 
antigen in order to evoke an antibody response. This sensitisation, 1 or 5 weeks before 
transplantation, resulted in graft survival of minutes to hours for both liver and heart grafts. 
The differences found between liver and heart graft survival in the sensitised situation may be 
explained by the difference in survival readout for the grafts. It is known that rats can live for 
several hours after total hepatectomy with just a portal caval shunt 7. 
At necropsy, massive antibody depositions could be detected in heart grafts from 
I-week sensitized recipients. Extravasation of erythrocytes, edema, fibrosis and vascular 
congestion, suggesting complement-mediated endothelial damage, indicate an ongoing HAR. 
Liver grafts from recipients sensitised 1 week before transplantation, however, showed an 
overall intact morphology and only marginal signs of HAR. This corresponds to their 
phenotypic appearance after grafting. Yet, classical signs of HAR were noted in liver grafts 
from 5-week sensitized animals: acute liver cell degradation, extensive tissue damage, and 
extravasation of erythrocytes. Purple recolouration and swelling were noticed after 
reperfusion. lmmunohistochemistry showed IgG depositions, whereas no graft depositions 
could be found in rats sensitised at week -1. 
Circulating Igl\il, present one week after sensitization, is likely to deposit on the heart as well 
as liver grafts. However, the results indicate that liver grafts, in contrast to heart grafts, seem 
to be less affected by IgM as seen by immunohistochemisty and complement depositions. One 
possibility is That the liver is releasing blocking agents, preventing antibody deposition, which 
has been hypothesised by Kamada et al 26. Another explanation is that graft size difference 
gives rise to difference in deposition density and therefore rejection. However, a more likely 
possibility is that Kupffer-cells absorb large amounts of lymphocytotoxic antibodies 2728. 
l\iloreover, Crafa et al 29 reported that Kupffer cell activation led to significant reduced 
circulation of anti-donor antibodies and a more intense IgM uptake after discordant liver 
grafting as demonstrated by immunohistochemistry. In the present study, however, liver grafts 
showed minor IgM depositions. Other authors have reported similar findings. T usa et al 30 
demonstrated that xenogenelc extracorporeal liver perfusion resulted m minimal 
immunohistochemical evidence of binding of human xenoantibodies. Nevertheless, reduced 
antibody binding to other organs was found after xenogeneic liver perfusion 30. Even prolonged 
heart xenograft survival has been reported after preceding xenogeneic liver transplantation 31. 
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This indicates that liver grafts, unlike heart grafts, are less susceptible to antibody-mediated 
damage, probably because of absorption or non-binding of antibodies, possibly IgM. 
Five weeks after sensitisation, mainly IgG type antibodies prevail. Histology of rejected livers 
showed a severe HAR with IgG and complement deposition, which were not detected in the 
grafts after recipient sensitisation at week -1. It seems, therefore, that IgG, specifically some 
IgG subtypes, may be responsible for the rejection process in liver grafts. In addition, several 
authors found that in experimental allogeneic liver transplantation after recipient sensitisation 
graft failure was dependent on the antibody class being IgG 32,33. Moreover, IgG, in contrast to 
IgM, seems to be the most dangerous in clinical allotransplantation across positive 
crossmatches 34.35. The minor damage seen in liver grafts of I-week sensitized recipients might 
be caused by the already formed, relative low titres of IgG. 
This could also explain why in discordant grafting no signs of HAR were seen, because most 
XNAs are of the IgM type 3.4.7.36. 
In conclusion, this study suggests a more dominant role for IgG over IgM antibodies in the 
rejection ofliver xenografts. Such predominance does not exist for heart grafts. 
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ABSTRACT 
Introduction. Currently, xenogeneic extracorporeal liver perfusion is used in the treatment of 
acute liver failure. In order to determine whether transgeneity for human regulatory proteins 
could improve the functional outcome of the ex vivo liver in relation to the histopathological 
changes, we studied the effect of the humoral mechanism in xenogeneic isolated rat liver 
perfusion in normal and transgenic rat livers. 
Alaterials and lvlethods. Isolated rat liver perfusion was performed for 2 hours in normal rat 
livers with Krebs Henseleit (KH) and human serum (HS), and in livers transgenic for human 
DAF (Tg HS). Function of the liver was established through measurement of liver enzymes, 
bile production and clearance of bromosulphophtalleine (BSP). Tissue specimens taken after 
perfusion were analyzed using routine histology and immunofluorescent staining for C3c-
deposition. 
Results. No change in release of liver enzymes could be established throughout the perfusion 
period. In the second hour, a higher level of bile production was seen for the transgenic group, 
compared to the HS group. The transgenic rat livers outperformed the normal livers perfused 
with human serum, when BSP concentration in the bile was measured, however, clearance of 
BSP from the perfusate was not significantly different. HE-staining of the liver tissue showed 
evidence of hyperacute rejection in the HS group. There was only mild tissue injury in the 
transgenic liver. High intensity fluorescent staining for C3c-deposition was seen in the normal 
livers perfused with HS and significantly less in the transgenic livers. 
Conclusion. Although histologically less tissue damage and less C3c-deposition was shown, 
no significant improved function of the livers transgenic for human DAF was established. 
These results suggest that for short term extracorporeal liver perfusion transgenesis offers no 
functional benefit. 
INTRODuCTION 
Less than 20% of the patients with fulminant hepatic failure survive when treated with 
conservative medical measures 1. Liver transplantation, at present the only therapeutical 
option with a survival rate of 80-90%, is limited because of the amount of -on time- available 
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donor organs. Therefore, a system capable of temporary supporting patients with liver failure 
is needed to bridge either to liver regeneration or to liver transplantation. 
In the early 1970s, as well as in recent years, ex vivo whole liver perfusion was clinically 
applied showing temporary improvement of the patient's clinical condition 2-4. In these 
xenogeneic perfusions, evidence of tissue damage to the ex vivo liver was established, 
however, the pathogenesis of injury was not consistent with hyperacute rejection 5. It seems 
that the liver is less susceptible to humoral injury, however, the effect of the humoral 
mechanism on liver perfusion remains to be determined. 
Because of the critical role of complement in hyperacute rejection, the development of 
transgenic animals expressing species-specific complement inhibitors could provide a strategy 
for overcoming damage by the humoral mechanism. For instance, the human complement 
inhibitor human decay accelerating factor (hDAF) prevents the assembly of C3 and C5 
convertases, and was shown to be variably expressed in different cell types oftransfected pigs 
6. And indeed, hearts 7,8 and kidneys 9,10 transgenic for hDAF have successfully been tested 
without hyperacute rejection in xenoperfusion and xenotransplantation. In isolated liver 
perfUsion, Adham et aJ showed a significant decrease of complement levels without 
significant alteration in liver function 11 and only mild histological evidence of hyperacute 
rejection 12 during xenogeneic perfusion of normal pig livers with human whole blood. 
However, in another study, Pascher et al 13 showed a marked complement activation and 
morphological damage in normal pig livers perfused with human whole blood, confirmed by 
an increase of the concentration ofliver enzymes, as compared to livers transgenic for hDAF. 
Although reduction in activation of human complement and hepatocellular damage in organs 
transgenic for hDAF in this study were shown, no evidence of changes in liver function was 
reported. Also, it is not clear whether these effects may be solely due to humoral mediators or 
to other components present in human whole blood. 
Therefore, in our study, isolated rat livers were perfused with human serum using organs from 
normal animals and animals transgenic for hDAF to determine whether this transgeneity 
could improve the functional outcome of the ex vivo liver related to the histopathological 
changes. 
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MATERIALS AND METHODS 
Animals. 
Experiments were petformed using male Wistar rats weighing 350-450 g and Sprague Dawley 
rats transgenic for human DAF weighing 400-500 g. hDAF transgenic rats were generated as 
described by Charreau et a1 14. Briefly, a construct containing the hDAF cDNA was used 
under the transcriptional control of the endothelial cell-specific human ICAM-2 promotor. 
DAF expression was evaluated by immunohistology in several organs including heart, lung, 
kidney, liver and lymphoid organs, and by F ACS-analysis of purified endothelial cells of 
heart and lung. Consistent levels of DAF were detected and showed uniform expression on 
the endothelium of all blood vessels. The rats were allowed free acces to water and rat chow 
before the isolation of the liver. The animals were divided into 3 groups: group 1 (n=6), 
perfusion of normal rat livers with Krebs Henseleit (KH), group 2 (n~6), perfusion of normal 
rat livers with 15% human serum (HS), and group 3 (n~6), perfusion with 15% human serum 
of livers from Sprague Dawley rats transgenic for hDAF (Tg HS) During the perfusions bile 
production, BSP-c1earance and biochemical parameters of the liver (AP, ALAT,ASAT, and 
LDH) were measured. Immunohistochemistry was performed to asses the deposition of 
complement in the rat liver. 
Surgical Protocol. 
The animals were anaesthetized with ether and a midline laparotomy was performed. The 
intestines were placed in a warm saline-moistened swab to the left of the animal. The median 
and left lateral lobes of the liver were mobilized by division of the suspensory ligaments, and 
the entire liver everted onto another warm saline-moistened swab on the thoracic cavity. The 
procedure exposed the portal vein and bile duct for cannulation. A 5/0 silk ligature was placed 
around the bile duct, and the duct was cannulated with a 2FG cannula filled with PBS 
(Phosphate Buffered Saline, Sigma P-4417). The subsequent capillary pressure enabled a 
good bile flow. The vena porta was ligated and cannulated and perfusion with oxygen 
saturated Krebs Henseleit medium started immediately. The infrahepatic caval vein was cut to 
improve outflow of the medium and a homogenous, pinkish-brown colour of the liver was 
established. The suprahepatic caval vein was cannulated after opening the thoracic cavity and 
the infra hepatic caval vein was ligated. The hepatic artery was left open to ensure moistening 
of the liver during perfusion. The liver was left in situ and the whole animal is transported 
into the perfusion system. 
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Peljusate Preparation. 
Perfusion was performed with Krebs Henseleit (KH) with 0.1 rnM Bromosulfophtalein (BSP, 
Fluka Chemika, Riedel-de-Haen, 19360) and 0.6% Bovine Serum Albumin to bind the BSP in 
solution (BSA, Boseral, Organon Technika). Human serum (HS) is collected from coagulated 
blood from human donors. It is centrifuged at 2000 rpm (MSE Mistral, Beun-de Ronde BY), 
after which the serum is filtered through a 220 )lm filter (Stericup Millipore Bedford, 0.22)lm 
GP Expres Membrane P25531). It is added to KH at a 15% dilution at which concentration 
hyperacute reaction can still be studied 14 and less serum is needed. 
Perfusion Technique. 
The perfusion system consisted of an oxygenator and a liver reperfusion circuit connected in 
parallel to a common reservoir. The circuit tubing was composed entirely of Silastic silicone 
rubber tubing with an internal diameter of2.0 mm and a wall thickness of 0.5 mm. The livers 
were perfused with a peristaltic pump at a constant pressure of22 cm H20 keeping a constant 
flow of 30-50mllmin depending on the size of the liver. The oxygenator existed of two parts 
passing a mixture of 95% oxygen and 5% carbon dioxide through the module, keeping the 
oxygen pressure at approximately 500 mmHg, necessary for sufficient oxygen diffusion to the 
liver tissue in the absence of oxygen carriers. The liver was perfused with KH for 20 min 
without reperfusion untill a uniform pale beige appearance of the liver is obtained, followed 
by a continuous antegrade reperfusion for 120 min at room temperature with a total volume of 
150 ml perfusate. 
Sample Collection and Immunohistochemical Analysis. 
Bile is collected every 10 min. directly form the bile-cannula into an Eppendorf cup. The 
actual amount of bile produced is calculated by measuring the weight of the cup before and 
after bile collection using a density of bilirubin of 1 glmI. Flow was monitored constantly 
throughout the perfusion and 0.5 m! samples of the perfusate were obtained from a seperate 
port directly after the liver every 10 min. About 100 ).ll is immediately stored in the 
refrigerator for BSP measurement, the rest is stored in the -20°C freezer for the biochemical 
analysis. At the end of the experiment samples of liver tissue were stored in formaldehyde and 
at -80°C. Formalin fixed tissue was paraffin embedded, cut and stained with haematoxylin-
eosine for examination of morphological changes by conventional light microscopy. FITC-
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conjugated rabbit anti-human C3c antibodies (Ra-aHuC3c/FITC, Dako ITK Denmark, Code 
No. F0201) were used to demonstrate complement deposition by fluorescence microscopy 
(Leica, Dl'vIRXA, No. 183235). Quantification of the C3c staining was performed by 
assessing the amount and intensity of the fluorescent spots in 2 slides from every experiment 
at 5 at random chosen fields of view. It was graded from 0 for no fluorescence to 5 for 
maximal fluorescence. 
Statistical analysis. 
The two-sample students T-test wit.h a 95% confidence interval was used for statistical 
analysis. 
RESULTS 
Function of the liver 
No increase in concentration of ASAT, ALAT, LDH and AF could be established during 
perfusion of normal rat livers with Kreb's Henseleit, human serum, or the livers transgenic for 
hDAF perfused with human serum, and no difference in concentration was found between the 
experimental groups (data not shown). 
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Figure 1. Bile production (mean with se); * significant difference Tg HS versus KH (p<O.05). 
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Figure 1 shows the mean bileproduction during the perfusion. There was a constant bile 
production throughout the perfusion, when the liver was perfused with KH (43 ± 5.7 
IlIIIOmin) and HS (50 ± 4.7 lll/lOmin) An initial increase in the first 40 min. in 
bileproduction from 43 ± 4 !J.l/I0min to 64 ± 3.4 !J.l/IOmin was shown, when perfusion was 
performed with human serum in the transgenic liver. In the second hour of perfusion, the bile 
production of the transgenic livers is statistically significant higher than the bile production in 
the KH-group (p<O.05), but no significant difference was established between the Tg HS-
group and the HS-group. 
The concentration ofBSP was measured in the bile and ftgure 2 shows the cumulative release 
ofBSP into the bile. A steady increase for all groups is shown. In the last 20 min of perfusion, 
a significant difference (p<O.05) in cumulative BSP concentration in the bile was measured 
between the transgenic group and the HS group. No significant difference was established 
from the KH group with either other group. 
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Figure 2. Cumulative concentration of BSP in bile (mean with se); * significant difference 
Tg HS versus HS and KH (p<005) 
The mean decrease of the concentration of BSP in the perfusate as a percentage of the 
concentration at the start of the perfusion is shown in figure 3. When the perfusion was 
performed with human serum in the normal liver as well as in the transgenic liver, 
significantly more BSP was removed from the perfusate as compared to the perfusion with 
KH (p<0.05) 
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Figure 3. Concentration of BSP in the perfusate as a percentage of the concentration at the 
start (mean with se); * significant difference KH versus HS and Tg HS. 
Immunohistochemistry of the liver 
Figure 4 shows the parafin embedded slides of the livers with a HE-staining 2 hours after 
perfusion with KH (fig 4a), perfusion with human serum in the normal rat liver (fig 4b) and 
the transgenic rat liver (fig 4c). After perfusion with KH for 2 hours a normal hepatic 
structure can be seen. Perfusion with human serum of the normal rat liver shows a 
disintegration of hepatocyte plate architecture, with damaged endothelium and endovascular 
fibrin deposition. Histological examination of the transgenic livers shows a mostly intact 
hepatic structure with no damage to the vascular endothelium. 
TABLE] 
Quantification ofC3c staining by assessing the amount and intensity of the flusorescent spots 
in 2 slides from every experiment at 5 at random chosen fields of view (0 for no fluorescence 
to 5 for maximal fluorescence). 
Experimental groups 
", KH (negative control) 
I
'HS 
TgHS 
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Assessment of fluorescence intensity 
0.13 ± 0.02] 
2. J ± 0.25 
0.93 ± 0.16 
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Figure 4. HE-staining of parafin embedded normal rat liver after 2 hou rs of perfusion with KH (A), 
human serum (8) and rat liver transgenic for hDAF with human serum (C). 
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In figure 5, immunofluorescent studies of the livers perfused with KH (fig Sa), human serum 
in normal (fig 5b) and transgenic livers (fig 5c) are shown. Evidently, there is more staining in 
the non-transgenic liver perfused with human serum as compared to the livers transgenic for 
human DAF, whereas the livers perfused with KH were taken as a negative control. Semi-
quantification of the amount and intensity of fluorescence is presented in table 1. Significant 
more C3c-deposition is shown in normal rat livers perfused with human serum compared to 
transgenic livers as well as compared to the livers perfused with KH (p<O.05). 
DISCUSSION 
In our model, the isolated liver perfused with human serum or Kreb's Henseleit showed good 
function throughout the perfusion period, as has been demonstrated by bile production, 
concentration of BSP in the bile and decrease of BSP from the perfusate. Perfusion with 
human serum accounted for a significant higher bile production as compared to perfusion 
with KH suggesting an advantage in the xenogeneic situation, possibly due to the content of 
the human serum versus KH. Overall, although no significant differences could be 
established, perfusion with human serum has a tendency to benefit the function of the isolated 
perfused rat liver. 
The livers transgenic for hDAF possibly showed a better function than the normal rat livers. 
After an initial increase, the bile production is significantly higher in the transgenic livers, 
there is more release ofBSP into the bile and, most importantly, the decrease of concentration 
ofBSP from the perfusate was higher. The initial increase of bile production in the transgenic 
liver may be due to the adjustment of the liver in the first 20 min., in which period it has been 
shown that complement and preformed natural antibodies are removed from the serum 11. 
This removal seems to be more efficient in the transgenic livers as compared to the normal rat 
livers since bile production remains at a lower level in these organs. 
Evidently more tisue damage was found in the normal rat liver compared to the transgenic rat 
liver on histopathological examination. Damage to the vascular endothelium and fibrin 
deposition in the normal rat liver suggests complement mediated tissue damage, indicating 
hyperacute rejection. On immunofluorescent examination, these findings were confirmed, 
showing significantly more C3c-deposition in the normal rat liver compared to the transgenic 
rat liver, indicating more humoral damage to the isolated nontransgenic rat liver. The extend 
of tissue damage was not sustained in release of Ever enzymes into the perfusate. Very low 
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levels of transaminases, lactate dehydrogenase and alkalic phosphatase could be detected in 
the perfusate and no difference could be established bet\Veen the experimental groups. Either 
our detection methods were not sensitive enough or the extend of tissue damage was not of 
major importance. However, the histopathological prove of tissue damage is convincing, 
parallel with a possible improved function of the perfused liver, and we therefore believe that 
a protective role of trans genesis has been established. 
The exceptional position of the liver in the xenogeneic situation complicates the interpretation 
of the possible beneficial role of transgenesis for complement regulatory proteins in ex vivo 
liver perfusion. Xenogeneic perfusion of the heart causes hyperacute rejection and immediate 
dysfunction of the heart within 10 min., whereas transgenic hearts function for several hours 
14. In xenogeneic perfusion of the isolated normal liver with human whole blood 12 and 
xenotransplantation of the normal liver in a discordant model 15 no hyperacute rejection has 
been shown. An immediate decrease of xenoreactive natural antibodies and complement in 
xenogeneic liver perfusion has been established in several reports 16,17, the effect of which 
was not always seen on histological examination 12, as we showed in this study. However, it is 
known, that pig livers expressing hDAF on the endothelial cell surface exhibit less tissue 
damage, down-regulate complement activation and therewith the release of some cytokines 
during the humoral reaction 13,18. Thus, although the normal liver seems to be capable of 
resisting the hyperacute rejection for several hours, the additional down-regulation may prove 
to be beneficial for isolated perfusion of the liver in terms of tissue damage and cytokine 
release possibly enabling a more effective use of the ex vivo liver for a longer period of 
time. Next to the use of organs transgenic for complement regulatory proteins on the 
endothelial cell membrane, other means to possibly reduce humoral damage in xenogeneic 
liver perfusion are under investigation. A reduction of the humoral effect was shown 
perfusing pig livers with human whole blood using continuous administration in the perfusion 
circuit of soluble complement receptor type I (300 Ilglml) 19 An additional study showed a 
remarkable increase in bile production and prolonged survival of a dog with ischaemic 
induced liver failure, which was extracorporeally assisted using pig liver perfusion with 
continuous adiministration of soluble receptor type 1 20. Using immunoapheresis with an Ig-
thereasorb 100 column, consisting of sheep-anti-human IgG antibodies covalently coupled to 
Sepharose CL-4B, Pascher et al significantly reduced the amount of circulating antibodies and 
complement, and revealed a significant reduction of cellular damage and functional 
restrictions of the ex vivo liver 21,22. However, immunoadsorption alone was not able to 
prevent organ damage or loss of function completely 23. In subsequent autologous reperfusion, 
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Figure 5. C3c-deposition in a normal rat liver after two hours of perfusion with KH (A), hwnan serum 
(B) and in a rat liver transgenic for hDM perfused with human serum (C). 
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the liver did not regenerate to it's initial level of performance, therewith pleading for the 
possible benefit of multiple short term ex vivo liver perfusions as opposed to a single long 
tenn perfusion, and the use of combinations of humoral damage reducing therapies. Despite 
the exceptional position of the liver in the xenogeneic situation, these studies confirm that a 
reduction of the humoral reaction clearly improves the outcome of xenogeneic ex vivo liver 
perfusion. 
In conclusion, in our study, rat livers transgenic for hDAF are protected from tissue damage 
following perfusion with human serum, which does not result in a significant improved 
function of the isolated liver. However, the beneficial effect of transgenesis in xenogeneic 
perfusion of the isolated liver on tissue damage and the consequent release of cytokines and 
other cell products may provide better functional results in long term extracorporeal liver 
perfusion and may provide a safer microenvironment for the treatment of patients with acute 
liver failure. 
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Introduction 
In the past 40 years numerous therapies have been developed and evaluated for the treatment 
of acute liver failure (ALF) 1,2, the most successful of which has been the orthotopic liver 
transplantation (OLT) from cadaveric donors 3, since it is known that only 20% of the patients 
with ALF survive when treated with conservative medical measures. Recent programs 
introduced the living related liver transplantation as an alternative source for cadaveric donor 
transplantation, which shows very encouraging results with survival rates of up to 90% in 5 
years 4.However, this potential large group of donors is limited for several reasons, e.g. blood 
group mismatch, size discrepancy, use of medication, age or preexistent other disease, 
providing a donor organ in only 30% of cases 5. Therefore, mortality rates in liver failure 
remain high. The shortage of donor organs for OLT and the lack of satisfactory means for 
temporary treatment to bridge to either liver regeneration or to liver transplantation, has 
renewed the interest in old and new methods for an extracorporeal approach to the treatment 
of ALP 26,31. The current opinion is that the mUltiple and complex functions of the liver can 
only be replaced using the biologic substrate (i.e., hepatocytes), whether in a whole liver or in 
combination with artifical material. By using xenogeneic biologic material in the treatment 
modalities of patients with liver failure, several health hazards are introduced. In an already 
immunocompromized patient, short- and long-term immunological problems can be expected, 
and transmission of viral material to the patient is possible. In this review, the problems 
encountered in the interaction between the xenogeneic device and the patients with liver 
failure are discussed and directions for future research are given. 
Existing temporary liver support techniques 
The lack of successful temporary assistance may be due, in part, to an incomplete 
understanding of the underlying mechanisms causing acute liver failure. Several lower and 
middle molecular weight substances have been blamed for playing a role in hepatic failure, 
e.g. bilirubin, bile acids, digoxin-like immunoreactive substances, indoles, phenols, 
mercaptans, endogenous benzodiazepines, aromatic amino acids, ammonia and lactate 6-9. 
They are thought to rapidly accumulate and cause multiple organ dysfunction and hepatic 
encephalopathy, eventually leading to hepatic coma as a life threatening complication of liver 
failure. Some of these endogenous toxins are water soluble, but most of them have a high 
binding affinity to albumin, a molecule overloaded with toxins in hepatic failure due to the 
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reduced detoxification capacity of the liver. For example, the limited binding capacity of 
circulating albumin for nitric oxide could be one mechanism of the decreased blood pressure 
and the need for pressors in hepatic failure when albumin bound toxins reach critical blood 
levels JO.ll. Furthermore, accumulated free toxins cause direct damage to the liver itself 
therewith creating a vicious circle of hepatic deterioration 12. Therefore, many devices have 
been developed concentrating on the detoxification function alone without having the 
negative side effects that arise from bioincompatability and lack of selectivity 13,14. 
Unfortunately, to date, these systems have not been able to improve the clinical status of the 
patient with liver failure because of low efficacy or because of the additional removal of 
factors that are essential for liver regeneration. 
A second method providing possible treatment for patients with acute liver failure involves 
the use of isolated human hepatocytes transplanted into the patient's liver or spleen IS. The 
additional integration of cellular components might complete the wide spectrum of functions 
that are necessary for successful treatment of hepatic failure 16. Highly differentiated function 
and significant prolonged survival has been shown when a clonal human hepatocyte cell line 
was transplanted into the spleen of 90% hepatectomized rats 17. In a single case human study 
18, 96% viable human hepatocytes were intraportally infused under cyclosporin 
immunosuppression, showing a complete recovery of the patient after regeneration of the 
patient's liver. In another study, five patients with grade III to IV hepatic encephalopathy 
were treated with hepatocyte transplantation either intrasplenic, intrahepatic or a combination 
of both under cyclosporin immunosuppression and temporarily showed subsequent substantial 
improvement in encephalopathy scores 19. However, in these reports, no sufficient control 
group was monitored. Moreover, first, the large scale isolation, culture and cryopreservation 
of human hepatocytes showing long term stable highly differentiated function needs 
optimization, and second, the shortage of donororgans necessary for the isolation of human 
hepatocytes limits the use of this procedure. 
Besides the above mentioned non-xenogeneic techniques, ex vivo liver perfusion, in which a 
whole organ is connected in parallel to the patient's circulation, has been developed and 
optimized for clinical use in the 1960s and early 1970s 20-23 This method has been applied 
with various results, but because of the successful development of the OLT in the 1970s, it 
was abandoned. During the last 10 to 15 years, a renewed interest in this temporary liver 
support technique has evolved. After 20 years, the disadvantages of OLT become clear: it is a 
major and costly procedure resulting in lifelong immunosuppressive therapy for the patient, 
and in 20% of cases a liver does not become available for transplantation in time 24. 
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Therefore, recently, studies were performed, which again showed promising results usmg 
extracorporeailiver perfusion in the treatment of patients with liver failure 25,26. 
Recent advances in tissue engineering have encouraged the development of a fourth method 
for temporary assisting the failing liver: the bioartificial liver device 27-31. In these systems, 
the biologic material, now consisting of hepatocytes only, incorporated in a synthetic 
framework, may provide a practical and save system to treat patients with liver failure. From 
the early studies of hepatocyte culture 3233, there has been an increasing effort to create a 
culture system, large enough to replace the function of a normal human liver, but small 
enough to provide an extracorporeal perfusion circuit without haemodynamic disadvantages 
for the patient. Using primary hepatocytes, a stable highly differentiated function for a longer 
period of time has not yet been established, as has been difficult in the smaller scale 
hepatocyte culture systems 34. Hepatoma cell lines (e.g. Hep G2 cells) have been used 
therewith avoiding this problem, but their function is inferior to primary hepatocytes as the 
source of hepatic function 35. Moreover, Hep G2 cells were detected in the extracapillary 
compartment of the bioartificial1iver, analogous to the patient's compartment during clinical 
application, which strongly suggests the possibility of tumor transmigration into an already 
immunocompromised patient 35. Therefore, the development of the bioartificial liver is 
focused on short term stable function of primary hepatocytes within an artificial system, e.g. 
for 6 to 8 hours, after which a new batch of hepatocytes is needed for effective extracorporeal 
treatment. Applying this technique, encouraging results have been obtained 31, but further 
clinical studies need to be undertaken, not only to improve the current available systems, but 
also to achieve a better understanding of the many facets of liver failure so as to best care for 
patients affected by it. 
The potential hazards 
With the introduction of the biologic material in the treatment modalities of patients with 
acute liver failure, several health hazards are introduced into the treatment. First, a patient 
with hepatic failure has a decreased coagulation capacity and a decreased immunological 
defense, possibly due to a decreased synthetic function of the liver. The patient is hooked up 
to a tubing system, which, whatever biocompatible material is used, may cause coagulation 
and infectious problems of its own. Second, depending on the volume of the extracorporeal 
perfusion circuit, an already haemodynamically instable patient may experience even more 
haemodynamic and metabolic changes during ex vivo treatment. Third, although 
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immunocompromised, the patient may be sensitized to the animal material used in the ex vivo 
system, possibly causing health hazards in the patient's future. Fourth, the release of animal 
material, e.g. porcine endogenous retrovirus (PER V), into the circulation of the patient may in 
the long run endanger the patient and its environment. At present, these issues play a 
predominant role in the development of xenogeneic liver support systems as well as their 
acceptence in society, for which reason they will be discussed next. 
Host versus Graft 
The humoral response plays a predominant role in the ex vivo treatment of patients \\lith liver 
failure, because the treatment is intended to last for several hours. In xenotransplantation, the 
hyperacute rejection (HAR), e.g. complement mediated cytotoxicity, pathological cellular 
reactions and humoral mechanisms by preformed naturally occurring antibodies (pNAbs), has 
been observed within a few hours 36. These pNAbs are directed against the GAL-alpha 
membrane epitope, the most important target antigen of the human humoral defense against 
porcine organs 37. There are two major factors when the temporary treatment of patients with 
liver failure is considered from an immmunological point of view. 
First, the patient suffers from liver failure, resulting in a decreased synthetic function, 
accounting for a decrease of the components of the immunological reaction. It has been found 
that the amount of complement in patients with ALF is significantly reduced 38, whereas no 
decreased levels of pNAbs were observed. Also, when ALF is induced in rats, a decreased 
level of complement correlated to a significant increase in xenograft survival is noticed, 
although a decrease in complement deposition was not established 39. Second, the liver has an 
exceptional capacity to remove antibodies from a perfusion circuit without being harmed, as 
compared with other organs. Immunohistochemical analysis of kidneys perfused with human 
blood demonstrates the binding of both IgM and IgG xenoantibodies and complement (C3) to 
kidney vascular endothelium, whereas staining was minimal for liver vascular endothelium, 
although levels of antibodies for both organs were significantly decreased after perfusion 40. It 
was suggested that the liver is capable of removing antibody and complement without cell 
lysis, possibly by endocytosis, compared with aortic or other endothelium 41. And indeed, in a 
recent clinical study using extracorporeal perfusion for the treatment of patients with acute 
liver failure, the disappearance of complement and antibodies was demonstrated without 
affecting the function of the ex vivo liver 42. Recently, an experimental study described the 
deviant role in hepatic xenografting of the antibodies, indicating a predominant role of IgG 
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over IgM 43. These results suggest that for short term use the function of the ex vivo liver is 
not affected by the patients immunological system. 
However, evidence of tissue damage in ex vivo liver perfusion has been established, which 
may cause a suboptimal function of the ex vivo organ and in return induce a hazard for the 
patient when breakdown products of the xenogeneic organ are released into the patient's 
circulation 44.45. In patients with liver failure treated with ex vivo perfusion, the level of 
pNAbs increased with the number of treatments per patient, indicating a possible cumulative 
effect of the xenogeneic perfusion 46, and in one patient an anaphylactic reaction was 
observed after 16 extracorporeai perfusions in 2.5 months 47. However innocent for short term 
use, long tenn or repetetive use of an extracorporeal system may indeed affect the function of 
the ex vivo organ and endanger the patient. 
In bioartificial liver support systems, a plasma separation unit is used and the communication 
between plasma and the isolated hepatocytes, or between the patient and the xenogeneic 
material, depends on the pore size used in the membranes of the bioreactor. The ideal nominal 
molecular weight cutoff (NMWCO) of the membranes may be between 50 and 100 kDa 
allowing breakdown products and proteins (molecular weight 0.6 to 70 kDa), essential for the 
health and recovery of the patient, to pass through, whereas the cytokines and 
immunoglobulins (molecular weight 100 to 900 kDa) preferably do not make contact with the 
liver cells 48. Theoretically, a humoral as well as a cellular immune response should be 
prevented in these systems. However, either through contact of the patient's plasma with the 
hepatocytes during perfusion or because of pig hepatocyte material entering the human 
circulation, it has been shown that sensitization has occurred in patients receiving several 
treatments with a BAL 49. In an experimental study, isolated porcine hepatocytes were 
exposed to 103 different human sera in the presence and absence of complement and tested 
for cytotoxicity 50. A range of 10 to 100% cytoxicity was found in the presence of 
complement, whereas no cell lysis could be established in the absence of complement. No 
membranes, however, were part of these experiments and therefore, these results may not be 
extrapolated to the actual situation in a hybrid BAL. 
Another factor to consider is whether xenogeneic bridging may sensitize the patient to 
subsequent allogeneic transplantation. Ye et al 51 showed no hyperacute, antibody-mediated 
or accelerated rejection in baboons, which received xenografts from pigs and African green 
monkeys, followed by allotransplantation. This mechanism seems to be unjustified, since the 
GAL-epitope is not prevalent in humans, and thus, the anti-pig-antibodies produced after 
xenoperfusion, are not directed against human cell surface proteins. 
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Graft versus host 
The risk to patients, posed by the transfer of (parts of) hepatocytes or other porcine cells from 
the ex vivo system to the patient, should be investigated. In extracorporeal whole liver 
perfusion, damage to the pig liver endothelium, as has been shown in the mild immunologic 
reaction in ex vivo perfusion, may cause transmission of animal material to the patient. As 
early as 1965, it was shown that C14_tagged glycine and lysine were incorporated into protein 
by the ex vivo pig liver, suggesting exchange of biologic material between graft and host 20. 
Also, pig serum proteins have been detected in the host circulation after whole-liver 
xenoperfusion 46. On the other hand, in a baboon-to-human liver transplantation, no baboon 
antibodies were detected in the human serum 52. Whether direct damage to the ex vivo liver 
mayor may not affect it's long term function and therewith the effectivity of the treatment of 
the patients with liver failure remains to be determined. Alternative strategies are developed 
to minimize the immunological effects in extracorporeal perfusion, for instance transgenesis 
53, the addition of soluble receptor type 1 54, and irnmunoapheresis 55. Improvement of the 
function of the ex vivo organ has been established, but the wished for effect on minimizing 
the amount of material that enters the patient's circulation and therewith the possibility of 
causing health hazards in the long run is still uncertain. 
Obviously, because of the absence ofa blood-endothelium contact, the hazards of xenogeneic 
interaction in bioartificial systems are less severe. However, the nature of the methods used to 
isolate hepatocytes for a bioreactor mean that non-parenchymal cells from the donor liver may 
get into the bioreactor, and therefore affect the patient. These include sinusoidal endothelial 
cells and also immune cells such as Kuppfer, PIT-and ITO- (Stellate) cells together with 
other cells circulating in the blood stream of the donor. With a NMWCO of 100 kDa, transfer 
of any kind of cell through the membrane of a bioreactor should not be possible. However, 
contact of the patients plasma to xenogeneic cells causes metabolic products of pig 
hepatocytes to enter the patients circulation and become immunogenic. Most products of the 
porcine liver would have to be taken into account since few of the macromolecules produced 
in the liver exceed the membrane nominal molecular weight cutoff. Lanza et al 56 seeded islets 
of porcine pancreas into diffusion chambers from permselective acrylic membranes with a 
NMWCO of 80 kDa, implanted intraperitoneally. Within 2 to 6 weeks, the recipients sera 
showed strong immunoreactivity, however, even after additional injection of "naked" islet 
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tissue into the peritoneal cavity, no anaphylactic or other immediate-type hypersensitivity was 
observed in the recipient. 
Table 1. Experiments performed to detect the infection of PER V in human cells in vitro. 
Reference Experiments Tissues tested Tvne test PERV infection 
Patience et al w Supernatant from Human kiciney-, Perv DNA positive 
Nat Med 1997 porcine kidney lung-, muscle-, Perv mRNA positive 
(PK15) cell-line Bcell-, and TceH 
culture culture 
i Co-culture of PK15 human embryonal PervDNA positive 
cells WiOl kidney cell line PervmRNA positive 
(HEK 793 cells) 
Martin et a1. I> Primary porcine! Perv DNA and Perv 
Lancet 1998 endothelial cells, 
, 
mRNA positive: 
hepatoCy1eS, lung-, capable of Pe:rv-
and skin cells infection 
Co-culture of with tIEK 293 cells Perv DNA i pos~t~ve 
porcine aortic Perv mRNA . pOSItIve 
endothelial cells 
Wilson et al. 0_ Peripheral blood Perv DNA and Perv 
J Viroll998 mononuclear cells· mRNA positive: 
(PEMe) mitogenic i capable of Perv-
activated \ViUl infection 
phytohemagglutinin 
I (PHA) and phorbol ! 
myristate acetate 
(PMA) 
i Co-culture 0[, with HEK 293 cells Perv DNA positive 
activated PBMe's PervmRNA I positive 
I Nyberg et al 03 Possibility of Pen' . Intraluminal Pen' DNA positive 
Transplantation transmission from a supernat,Ult Perv mRNA positive 
1999 hollow fiber 
cartridge. I , 
Intralwnina.l culture I 
with PK15 cells 
Supernatant of the HEK 293 cells after 
extralwninal space pore size 200 run DNNmRNA positive 
[rom above cultured pore size 10 run DNAJ111RNA negative until day 3 
on i pore size 5 run DNNmRNA negative until day 7 
i Nyberg el 81 .. CJ Porcine hepatocyles Pen' DNA and Perv 
, Liver Transpl. 2000 with nomlal mediwn mRNA positive: 
and serum from capable of Perv-
patients \vith infection 
fulminant hepatic 
failure 
, Supernatant of the HEK 293 cells, Perv DNA negative 
above cultures on supernatant of this Pen'mRNA negative 
culture tested for 
Mm1in et aI. tr1 Supernatant of PK 15 Human endothelial Perv DNA positive 
Xenotranspl. 2000 cells on cells and fibroblasts PervmRNA : positive 
Bone marrmv Pen' DNA positive 
stromal cells and PervmRNA negative 
mesan aial cells 
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One of the major concerns with the use of porcine organs in this manner is the threat of pig-
to-human transmission of activated endogenous retrovirus present in the pig genome 57. 
Porcine endogenous retrovirus (PERV) was described in 1973, but at that time was shown to 
be unable to infect human cells 58 However, the observation that PERV DNA and PERV 
RN A are detected in the supernatant of pig hepatocyte culture systems S9 and such viruses can 
infect human cell lines in vitro 60, has led to intense scrutiny of such research by regulatory 
agencies worldwide. Table 1 shows an outline of the six studies that have been performed 
thus far, in which the transmission and infection of PERV was examined in v;-tro 59-64. 
Productive PERV infection, detected with PCR (PERV DNA) and RT-PCR (PERV mRNA) 
has been shown from most porcine tissues into a human cell line (HEK 293), human 
endothelial cells and fibroblasts in culture. It is as yet unknown whether these findings 
represent in vitro artifacts or whether infection can occur in the in vivo situation. 
The experiments perfonned in vivo are summarized in table 2, representing two non-human 
and three human in vivo studies 6H9. PERV transmission was tested by PCR RT-PCR and the 
detection of anti-PER V antibodies in the serum of the acceptant. Thus far, in vivo PERV 
transmission has been established in non-obese diabetic, severe combined immunodeficient 
mice 66, but not in humans treated with porcine tissue, as has been shown by Paradis et a1 69 in 
a retrospective study of 160 patients. Infection only occurs if first, the provirus sequence in 
porcine tissue is activated to produce and release intact virus; second, in the case of a 
bioreactor, the virus must cross the semipermeable membrane and third, once in the patient's 
circulation, the virus must be capable of productively infecting human cells. In the BAL, the 
second step may be the limiting factor, as has been shown by Nyberg et ai., since the :MWCO 
of most bioreactors is between 50 and 100 kDA (pore size ± 5 nm), which prevented PERV 
infection in human cells for 7 days, whereas the therapy is intended to last for only a day at a 
time. Moreoever, the transmission of PER V to normal, healthy humans might be prevented by 
natural alpha-GAL binding antibodies and complement, as has been shown for other 
retroviruses 70.72. 
If infection is possible, one needs to determine whether the virus is transmitted by blood 
contact and/or by food, and why considerable segments of the human population are not 
PERV-positive. In xenogeneic treatment, the heavily immunosuppressed patient potentially 
has a lower titer of natural antibodies, including the anti alpha-GAL antibodies. This could 
result in a diminished virolysis of PERV particles. Furthermore, genetic modifications, such 
as the elimination of porcine GAL epitopes or the introduction of complement regulators, 
proposed to overcome hyperacute rejection, could promote the infection of human cells with 
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Table 2. Experiments peformed to detect the infection of PER V in humans in vivo. 
NON-HUMAN 
i Reference Experimental setup Tissues tested Time tested PERV 
Martin et al. " 1 Porcine aortic endothelia: I Baboon skin, liver. 12 yems after negative 
Transp!. 1nt. 1998 cells transplanted into :leucocytes, transplantation 
baboons with high dose' lymphnodes for DNA 
cyclophospl18.l11ide [or 0--1 and rnRNA 
davs 
Van der Law et a!. 6 Purified pig islets Transplantation site. 18 to 56 days positive 
Nature 2000 transplantation under kidney : spleen, liver, salivary 
capsule of non-obese gland, skiR small 
I 
diabetic. severe combined bowd, lung, kidney 
immunodeficient mice for DNA and mRNA 
I HUMAN 
I Reference Experimental setup Tissues tested Time tested PERV 
Heneine et a1. 0 i Porcine fetal pancreatic islets Blood lymphocytes, 14,5 to 7,5 years negative 
Lancet 1998 transplanted into 10 diabetic sera for DNA, mRNA: 
patients under and anti-PERV 
immlillosuppression antibodies I ( cyclosporin. prednisolone, 
azmhioprine) 
! Patience et al , E:xtracorporeal pig kidney Peripheral blood 6 hrs to 36 negative 
I 
Lancet 1998 i perfusion in 2 patients mononuclear cells i months after 
i perfusion 
Paradis et al. W 160 patients with: Peripheral blood Up to 12 years ! negative 
Science 1999 Extracorpore2.1 spleen, liver mononuclear cells and 
and kidney-perfusion, serum for DNA, 
cxlracopron::al perfusion wilh mRNA, and anti-
a bioarlificial liver, pig skin PERVantibodies 
I 
grafts, porcine pancreatic islet 
celllransplants i 
PER V 73. Scientists, physicians, and ethicists are currently discussing whether clinical trials 
should be postponed due to the risks ofxenozoonosis 73.76. In our country, a public debate has 
been initiated by the minister of health in december 1999, which to date has put a complete 
hold on clinical trials using xenogeneic material in the treatment of patients. Thus far, no 
transmission of pig endogenous virus was detected from porcine endothelial cells transplanted 
to baboons or humans. However, because of the variety of potentially dire consequences after 
clinical xenogeneic treatment in immunosuppressed patients, including the risk of patient 
disease and epidemic transmission of humanized viruses, preclinical models are needed to 
further evaluate this issue. 
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New possibilities in liver support therapy 
Although the knowledge of immunology and xenobiology has improved, the possible impact 
of xenogeneic treatment is still uncertain. Temporary treatment of patients with liver failure 
with conservative therapy or passive detoxification techniques is safe, but success rates are 
limited. The short term treatment with extracorporeal whole liver perfusion has a reasonable 
succes, with and without genetic modification of the ex vivo liver. It seems that genetic 
modification could potentially benefit the treatment modality, because evidently less damage 
is found in these livers after perfusion, suggesting a possible longer effective use of the organ. 
The impact of the xenogeneic interaction in the treatment of patients with liver failure with 
bioartifical liver systems seems to be minimal. Therefore, it is my strong opinion, that 
xenogeneic non~transgenic tissue or cells could be used in the short term treatment of patients 
with liver failure. 
In the mean time more permanent solutions to the problem of treating patients with liver 
failure should be pursued, which could eventually completely replace the above mentioned 
systems including their disadvantages. Several alternative sources of liver cells are under 
investigation. Newly developed immortalized human cell lines, e.g. NKc~T-3 cells and 
OU]\IS~29 cells, have been shown to express highly differentiated liver specific function 17.77. 
Another study shows the successful use of human foetal hepatocytes, harvasted from a liver 
obtained from mid-trimester abortions 78. Also, the function of freshly isolated porcine 
hepatocytes in a bioartificialliver may be improved, if the cells are pre-cultured for a longer 
period of time before inoculation 79. 
A possible indefinite source of hepatocytes for bioartificial means may be the use of stem 
cells 80. A stem cell can be defined as a cell that has the capacity both to produce daughter 
cells -'self-renewal'- and to produce daughters that are fated to differentiate -'commitment'-
(fig 1). Self-renewal plays a key role in these developments: first, because it enables the long 
term maintenance of grafts of renewing tissues, and second, because it provides a large scale 
production. Stable differentiation or commitment is necessary to eventually enable the 
repetetively culture of the cell type of interest. Efforts to isolate, expand and genetically 
manipulate stem celts from adult tissues have to date met with only partial success 81. An 
alternative to the primal)' derivation of tissue-specific stem cells would be the development of 
an in vitro system in which lineage-restricted stem cells could be generated from a founder 
stem cell population of human pluripotent stem cells (HPCs) These cells, with the capacity to 
generate all foetal and adult cell types, exist only in the early embryo and in a particular type 
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of germ cell tumour, teratocarcinoma. HPCs from teratomacarcinomas have been established 
in culture, but their tumour origin makes them unsuitable for therapeutic exploitat ion. In mice, 
however, the isolation of teratoma carcinoma stem cells was followed by the derivation of 
non-transformed pluripotent stem cells directly from embryos 82 . These cells proved to be 
pluripotent, immortal and phenotypically stable in vitro and in vivo 83-85. The isolation of 
HPCs analogous to mouse embryonic stem cells would thus create the possibillity of 
generating human cells for transplantation. Recent ly, Thomson et al 86 have been able to 
derive pluripotent embryonic stem cell lines from human blastocysts, that have normal 
karyotypes, express high levels of telomerase activity, which is known to play an important 
ro le in the replicative life-span, and express cell surface markers that characterize primate 
embryonic stem cells but do not characterize other early lineages. 
~')l:r. 
Self-renewal Ci~) Pluripotent 
Stem Cell 
Commitment / ~ommit11lent 
O!) O!) 
Blood Stom Cells Other committed 
J '" Stom Colis 
,. ~ ~ (e.g. hepatocytes) 
Specialized [Red Blood Whijo Blood 
Celis Coils Plato lots Cells 
Figure 1 In this figure, the development of the totipotent celi into the pluripotent 
stem celi is given, at which stage it is harvasted from the blastocyst . The further 
development should reassure the self-renewal of the stem cell population in order 
to have an unlimited source of pluripotent cells and to provide large scale 
production of a specific cell type; comm itment should ensure the stable 
development of the cell type of interest, e.g. into d,ffere nt type of blood cells 
(arrow to the left) or other cell types, for instance hepatocytes (arrow to the right). 
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Although these results are encouraging, the overall availablity of human blastocysts is limited 
due to the fact that in many countries, research using pre-implantation stages of human 
development is not permitted. Eggs may be donated for research by couples receiving 
infertility treatment, or by couples who have completed such treatment and have eggs 
remaining frozen in storage, however, in many cases they turn out to be abnormal and fail to 
develop the blastocyst stage. An alternative route is to attempt to derive HPCs at later stages 
using aborted foetal tissue, as has been shown in mouse 87, pig 88, and recently also in humans 
89. However, the molecular basis of the pluripotent phenotype and the mechanism by which 
germ cells convert to embryonic stem cells are stil unknown. 
At present, stable pluripotent stem cell lines are being established, which show a 
heterogenous, disorganized differentiation, producing a mixture of cells, whereas the 
generation of a pure population of defined cell types is wanted. The characterization of 
inductive pathways that mediate lineage and cell-type-specific differentiation complemented 
by techniques for purifying specific cell types, e.g. by applying a genetic selection for 
expression of a marker gene, holds the key to progress 85.90 Although quality and 
differentiated function of stem cells are stil unknown, these cells may provide a readily 
available source without immunological drawbacks, host versus graft and vice versa, and 
therefore may hold the future of ~afe and effective cellular systems in the treatment of patients 
with liver failure. 
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SUMMARY 
In the past 40 years, various approaches have been used to treat patients with acute liver 
failure. Thus far, orthotopic liver transplantation has had the best results, with survival rates 
ranging from 80 to 90 %. However, mortality rates in liver failure remain high, because of the 
shortage of donor organs and the lack of satisfactory means for temporary treatment of 
patients with liver failure to bridge to either liver regeneration or to liver transplantation. 
Therefore, in this dissertation we further investigated the applications used to treat patients 
with a failing liver and studied in more detail the xenogeneic environment of the ex vivo 
hepatic support system. 
The general introduction and the outline to the dissertation are presented in chapter 1. 
Renewed interest has developed in old and new methods for an extracorporeal approach to the 
treatment of acute liver failure. Although temporary clinical improvement has been 
established, further research is needed to achieve a successful long-term clinical outcome. In 
chapter 2, a review is given in which the various approaches to temporary liver support as 
well as the immunologic and metabolic developments towards a solution for this problem are 
assessed. Their shortcomings are discussed and directions for future research are suggested. 
The successful development of a bioartificial liver relies, in part, on the ability to maintain 
viability and differentiated function of a large number of hepatocytes in vitro for extended 
periods of time. Microcarriers have been widely used to scale up anchorage-dependant 
mammalian cell cultures. In chapter 3, an attempt to create optimal culture conditions for 
hepatocytes attached to microcarriers is described. Hepatocytes cultured on gelatin-coated 
plastic microcarriers and embedded in type I collagen showed albumin and urea secretion 
rates comparable to that seen in small-scale long term culture systems. In addition, the 
specific albumin secretion rate obtained was similar to that found in vivo. Thus, long term 
liver-specific function can be induced by surrounding hepatocytes seeded on microcarriers 
with a collagen gel. This suggests that microcarriers might be useful in the development of a 
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large scale hepatocyte culture system expressing high and stable levels of liver-specific 
function. 
Transgenic pig livers are being used to study the feasibility of extracorporeal liver perfusion 
in the treatment of patients with acute liver failure. However, it remains to be determined 
whether non-immunological aspects may limit the quality of extracorporealliver perfusion. In 
chapter 4, an autogenous pig liver perfusion model was used to study the haemodynamic and 
metabolic changes in an ex vivo perfusion system. Microscopic examination of the liver 
demonstrated venous stasis mainly in the peripheral parts of the liver and although a good 
function of the liver was established, an increasing lactate-acidosis was measured, correlating 
with haemodynamic instability of the pig after approximately 3 hours of ex vivo perfusion. 
Thus, although the ex vivo liver may give adequate hepatic support, this autogenous model 
demonstrates that irrespective of immunological responses, physiological parameters limit the 
period of effective use of extracorporealliver perfusion. 
Thus far, effective temporary ex vivo liver perfusion has been applied without immunological 
drawbacks. Complement is known to play a major role in hyperacute rejection in 
xenotransplantation and the level of complement is significantly decreased in patients with 
acute liver failure. In chapter 5, we investigated the possibility of acceptance of a discordant 
xenograft in rats with acute liver failure induced by galactosamine. And indeed, an increase in 
xenograft survival time in rats with acute liver failure is shown, probably due to a significant 
decrease in complement levels and activity as can be measured in complement depleted rats 
induced by pre-treatment with cobra venom factor. This could mean that the use of livers 
from pigs that are transgenic for human complement regulatory proteins is not essential to 
enable uncompromised short term liver perfusion. 
The liver has been found to be less susceptible to humoral injury. For instance, no classical 
features of hyperacute rejection are found in liver grafts in the discordant guinea-pig-to-rat 
model. To further enlighten the underlying mechanisms involved in xenogeneic applications 
of the liver, discordancy is mimicked in the sensitized hamster-to-rat liver transplantation 
modeL By using different immunisation protocols, predominance of either IgG or IgM 
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antidonor antibodies was created. Transplantation of hamster heart or liver in both 
sensitisation models revealed a difference in rejection pattern between both organs. As 
described in chapter 6, a predominance of IgG over IgM was found regarding the hyperacute 
rejection of liver grafts. This difference in rejection was not found for heart grafts. 
The role of the hyperacute rejection remains obscure in xenogeneic extracorporeal liver 
perfusion. In order to achieve a better understanding of the humoral aspects of liver perfusion, 
and to study the possible benefit of the use of a transgenic liver, we determined the function 
and the immunopathological features of the isolated nonnal and transgenic rat liver perfused 
with human serum. It was found, as described in chapter 7, that although histologically less 
tissue damage and less C3c-deposition was shown in the livers transgenic for human DAF, 
there is no significant functional difference between the transgenic and non-transgenic liver 
perfusion. These results do suggest that the beneficial effect of transgenesis in xenogeneic 
perfusion of the isolated liver on tissue damage and the possible consequent release of 
cytokines may ensure a more effective long term use of the extracorporeailiver. 
At present, a number of major hurdles are to be taken in order to safely apply the hepatic 
extracorporeal perfusion modalities. These include the immunological implications of these 
techniques, e.g. the host versus graft reaction and vice versa, and the possible health hazards 
for the patient with liver failure and it's environment treated with a xenogeneic device. In 
chapter 8 these difficulties are described and the possible solutions for short term and long 
term treatment are discussed. 
SAMENVATTING 
In de laatse 40 jaar zijn veJe manieren toegepast om patienten met acuut leverfalen te 
behandelen. De beste resultaten worden tot op heden bereikt met de orthotope 
levertransplantatie, met overievingspercentages varierend van 80 tot 90%. Echter, de 
1110rtaliteit van leverfalen blijft hoog door het tekort aan donororganen en het ontbreken van 
adequate methoden om patienten tijdelijk te behandelen ter overbrugging naar 
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leverregeneratie of naar levertransplantatie. Om die reden wordt in dit proefschrift verder 
ingegaan op de bestaande methoden voor de behandeling van patienten met een falende lever 
en de xenogene omgeving van de lever wordt nader bestudeerd. 
In hoofdstuk j wordt een algemene introductie gegeven tot het onderwerp en wordt de inhoud 
van het proefschrift in grote lijnen uiteengezeL 
Er is hemieuwde belangstelling voor oude en nieuwe methoden in de ex vivo behandeling van 
patienten met leverfalen. Hoewel tijdelijke klinische verbetering is aangetoond, is verder 
onderzoek no dig voor succesvolle resultaten op de lange termijn. In hoofdstuk 2, wordt een 
overzicht gegeven van de verschillende manieren van extracorparele behandeling van 
leverfalen. De immunologische en metabole ontwikkelingen worden uiteengezet, de 
tekortkomingen worden besproken en mogelijkheden voor de toekomst worden gesuggereerd. 
De succesvolle ontwikkeling van een kunstlever is deels afuankelijk van de mogelijkheid om 
een groat aantal hepatacyten met een goed gedifferentieerde functie voar een langere periode 
in leven te houden. Microcarriers zijn veelvuldig gebruikt am de hoeveelheid menselijke 
cell en, die vaar een goede functie afhankelijk zijn van aanhechting, per volume te vergroten. 
In hoofdstuk 3 wordt een manier beschreven am optimale kweekamstandigheden voor 
hepatocyten aangehecht aan microcarriers te creeeren. Hepatocyten, gekweekt op met gelatine 
bedekte microcarriers en omgeven met type I collageen, lieten een albumine en ureum 
productie zien. die vergelijkbaar is met de productie in de kleinere kweeksystemen. 
Bovendien was de albumine productie vergelijkbaar met de in vivo albumine productie. 
Derhalve is gebJeken, dat een goede lever-specifieke functie verkregen kan worden door 
hepatocyten te kweken op micro carriers in type I collageen. Dit suggereert, dat het gebruik 
van microcarriers een mogelijkheid biedt, om een hepatocyten-kweek systeem op grate schaal 
te creeeren met een hoog en stabiel niveau van lever -specifieke functie. 
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Transgene varkenslevers worden gebruikt am de haalbaarheid van extracorporele 
Ieverperfusie bij de behandeling van patienten met acuut leverfalen te bestuderen, Echter, het 
is onduidelijk ofniet-immunologische factoren de kwaliteit van de ex vivo perfusie beperken. 
In hoofdstllk 4 wordt een autogeen varkensleverperfusiemodel beschreven, waarin de 
haemodynamische en metabole aspecten van het ex vivo systeem worden bestudeerd. 
Microscopisch onderzoek laat veneuze stase zien voornamelijk in de periferie van de lever; 
hoewel een goede functie van de lever verkregen werd, werd een toenemende concentratie 
van lactaat gemeten, correlerend met haemodynamische instabiliteit van het varken na 
ongeveer 3 uur perfusie. Dus, hoewel de ex vivo lever adequate functionele ondersteuning 
biedt, toont dit autogene model aan dat onatbankelijk van de immunologische reacties, 
physiologische parameters de periode van effectief gebruik van de ex vivo lever kunnen 
beperken. 
Tot nu toe is effectieve tijdelijke ex VIVO leverperfusie toegepast zander immunologische 
problemen. Van xenotransplantatie is bekend, dat complement een belangrijke rol speelt in de 
hyperacute afstoting, en ook weten we, dat patienten met acuut lever falen een significant 
verlaagd hoeveelheid circulerend complement hebben. In hoofdstuk 5 hebben we de 
mogelijkheid van de acceptatie van een discordant xenotranplantaat bestudeerd in ratten met 
leverfalen gelnduceerd door galactosamine. En inderdaad, een verlengde xenotransplantaat 
overleving wordt gevonden in deze ratten, waarschijnlijk door een significante daling van het 
circulerend complement zoals bekend bij complement gedepleteerde ratten door cobra venom 
factor. Dit betekent, dat het gebruik van levers van varkens transgeen voor complement 
regulerende eiwitten wellicht niet noodzakelijk is om ongecompliceerde korte termijn 
extracorporele leverperfusie mogelijk te maken. 
De lever is minder gevoelig voor antilichaamgemedieerde schade. Bijvoorbeeld worden geen 
verschijnselen van klassieke hyperacute afstoting gezien in het discordante cavia-naar-rat 
transplantatie model. Discordantie werd daarom nagebootst in een gesensitiseerd hamster naar 
rat model. Predominantie van of IgG of IgM antidonor antilichamen werd gecreeerd, gebruik 
rnakend van verschillende immunisatie protocollen. Transplantatie van hamsterhart en -lever 
in beide sensitisatie modellen onthulde een verschil in afstotingspatroon tussen beide organen. 
Zoals beschreven in hoofdstuk 6 werd er een predominantie gevonden van IgG ten opzichte 
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van IgM wat betreft hyperacute afstoting van de lever. Dit verschil in rejectie werd niet 
gevonden bij harttransplantaten. 
Het werkingsmechanisme van hyperacute afstoting in xenogene extracorporele leverperfusie 
is onduidelijk. Om de aspecten van de humorale reactie beter te besturen en het mogelijke 
voordeel van een trans gene lever boven een normale lever te analyseren hebben we de functie 
en immunopathologische kenmerken van de gelsoleerde normale en transgene rattenlever 
geperfundeerd met humaan serum bestudeerd. In hoofdstuk 7 wordt beschreven, dat hoewel 
histologisch minder weefselschade en minder C3c-neerslag werd gevonden in de levers 
transgeen voor humaan DAF, geen significant verschil in functie werd gemeten. Deze 
resultaten suggereren dat de verminderde weefselschade en de mogelijk daaraan verbonden 
verminderde productie van cytokines veroorzaakt door transgenese wellicht een langer 
effectief gebruik van de extracorporele lever mogelijk maken. 
Voor de veilige toepassing van extracorporele lever ondersteunende systemen moeten nog 
vele horden genomen worden, o.a. de immunologische implicaties van deze technieken, 
bijvoorbeeld de host versus graft reactie en vice versa, en de mogelijke gevaren voor de 
gezondheid van de patient met leverfalen behandeld met een xenogeen systeem. In hoofdstuk 
8 worden deze problemen besproken en mogelijke oplossingen voor korte en lange termijn ter 
discussie gesteld. 
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